MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
1of 98 Template 16.2A Phase 1b Randomized, Double -blind, Placebo -controlled 
Multiple -ascending Dose Study  to Evaluate the Safety , 
Tolerability , Pharmacokinetics, Immunogenicity , 
Pharmacody namics ,and Clinical Response of MEDI4920 in 
Subjects with A dult-onset Rheumatoid A rthritis
Sponsor Protocol Number: D5100C00002
Application Number: IND 128905
EudraCT Number : 2015 -005318 -30
Investigational Product: MEDI4920
Sponsor: MedImmune Limited, a who llyowned subsidiary  of 
AstraZeneca, Milstein Building, Granta Park, Cambridge, 
CB21 6GH, UK
Medical Monitor: , MD
, MedImmune
Phone:  Fax:
Contract Research Organization: ICON
Protocol History, Date : Original  Protocol , 15Jan2016
Protocol  Amendment 1, 05Apr 2016
Protocol  Amendment 2, 10 Aug2016
Protocol  Amendment 3, 29Sep 2017
This document contains trade secrets and commercial information that is privileged or 
confident ial and ma y not be disclosed without prior authorizat ion from MedImmune.
PPD
PPD
PPD
PPD
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
3of 98 Template 16.2•  
•
•
STUDY DESIGN   
This is a multicenter, randomized, double -blind (investigator, subject, and sponsor will be blinded to treatment 
assignment), placebo -controlled study to evaluate the safety and tole rability  of multiple ascending doses of 
MEDI4920 in subjects with adult -onset RA (moderate to severe, as defined by DAS28 CRP ≥ 3.2 at screening) 
with an inadequate response to MTX or other cDMARDs or a biologic anti -tumor necrosis factor alpha agent. 
The study is planned to be conducted at approximately 15 sites in 2to4 countries. A maximum of 54 eligible 
subjects are planned for this study. Approximately 40 subjects will be randomized in 3 cohorts to receive either 
75 mg (Cohort 1), 500 mg (Cohort 2), o r 1500 mg (Cohort 3) MEDI4920 or placebo Q2W in combination with 
MTX or another cDMARD for up to 12 weeks. An additional 14 subjects willbe randomized in a 5:2 ratio to an 
additional cohort (Cohort 4) to better characterize the dose (exposure) -response re lationship. The selected dose
of MEDI4920 in Cohort 4   is 1000 mg Q2W .
Cohorts 1 to 3 will start sequentially, with escalation from Cohort 1 to Cohort 2 and Cohort 2 to Cohort 3 
confirmed by a Dose Escalation Committee (DEC) comprised of MedImmune study te am members and the 
Study Global Chief Investigator, who will assess in a blinded fashion the safety/tolerability data after the last 
subject in a cohort completes Day 29 (Week 4) of treatment and has AE/safety laboratory data available at that 
time point. There will be a total of three DEC meetings during the study; the first DEC meeting will only review 
data from Cohort 1 w hereas the second DEC meeting will review cumulative safety data from the first two dose 
cohorts being tested to date. The third DEC me eting will constitute a thorough evaluation of the cumulative 
safety and tolerability data for Cohorts 1 and 2 in addition to the data up to Day 85 for Cohort 3. After the last 
Cohort 3 subject completes the Day 85 (Week 12) assessments, the primary analys is will be conducted to 
include safety, tolerability, PK, anti -drug antibody (ADA), biomarker, and clinical response. Based on the 
outcome of this analysis, a fourth cohort will be included to better understand the dose (exposure)- response 
relatio nship. Ea ch subject will participate in the study for up to approximately 30 weeks (includes a 6 -week 
screening period, a 12 -week treatment period, and a 12 -week follow -up period). A screening visit(s) will be 
performed within 6 weeks (42 days) prior to dosing. Allsubjects will receive investigational product on the 
morning of Day 1. An overnight stay on Day -1 prior to administration of investigational product on Day 1 is 
recommended but not mandatory . If no safety concerns are identified, subjects will be dischar ged from the study 
site on Day 2 (end of the inpatient treatment period) after all study procedures have been completed. Subjects in 
all cohorts will return to the study site Q2W (Days 8, 15, 29, 43, 57, 71, and 85) for investigational product 
administrati on and/or specific assessments and blood draws . During the treatment period, assessments of RA 
parameters as well as evaluations of safety, tolerability, PK, and immunogenicity of MEDI4920 will be 
performed. Following the final IV infusion of investigation al product, subjects will return to the study site for 
follow -up visits beginning at Week 13 (Day 92) and continuing through Week 24 (Day 169) to evaluate safety, 
tolerability, PK, and ADA of MEDI4920.
TARGET SUBJECT POPULATION   
Male or female adults 18-70 years of age, inclusive, with adult -onset RA diagnosed by European League 
Against Rheumatism /American College of Rheumatology 2010 criteria at least 6 months before screening.
TREATMENT GROUPS AND REGIMENS
A maximum of 54 subjects will be randomize d to receive either MEDI4920 or placebo as follows: 10 subjects 
will be randomized in Cohort 1 in a 4:1 ratio to receive 75 mg MEDI4920 (N = 8) or placebo (N = 2) as a single 
IV dose administered over at least 30 minutes Q2W; 14 subjects will be randomized in Cohort 2 in a 5:2 ratio to 
receive 500 mg MEDI4920 (N = 10) or placebo (N = 4) as a single IV dose administered over at least 
60minutes Q2W; and 16 subjects will be randomized in Cohort 3 in a 3:1 ratio to receive 1500 mg MEDI4920 
(N= 12) or placebo (N = 4) as a single IV dose administered over at least 90 minutes Q2W. An additional 
14subjects willbe randomized in Cohort 4 in a 5:2 ratio to receive 1000 mg MEDI4920 (N = 10) or placebo (N 
= 4) as a single IV dose administered over at least 90 minutes Q2W .
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
4of 98 Template 16.2STATISTICAL ANALYSIS METHODS 
Sample Size: 
No formal sample size calculations are presented for the evaluation of the primary objective of safety and 
tolerability of MEDI4920. The sample size calculations are based on the exploratory endpoint
 The sample size calculation for Week 12 
DAS28 CRP change from baseline is based on combining the data from the cohorts and performing a dose 
response analysis. Based on the assumption
 the sample sizes of 14, 8, 10, 10 and 
12subjects for the placebo, 75, 500 , 100 0mg,and 1500 mg dose groups, respectively, will provide 
approximately 92% power for detecting a statistically significant dose response, using a significance level of 
0.10. The power for dose response has been calculated using a multiple comparison procedure with modeling 
techniques with three candidate models for the dose response (linear, maximum e ffect attributable to the drug 
[Emax], and a Hill -Emaxmodel). An overall significance level of 0.10 will be used to test for dose response.
Statistical Analyses:
AEs will be coded using the Medical Dictionary for Regulator y Activities (MedDRA) by system organ class 
(SOC) and preferred term (PT). Specific AEs will be counted once for each subject for calculating rates, but will 
be presented in total in subject listings. In addition, if the same AE occurs multiple times within a particular 
subject, the high est severity and level of causality will be reported. If any associations of interest between AEs 
and baseline characteristics are observed, additional stratified results may be presented. All treatment -emergent 
AEs will be summarized overall and by MedDRA SOC and PT, by severity, and by relationship to 
investigational product. In addition, summaries of deaths, SAEs and treatment discontinuations due to AEs will 
be provided. Treatment -emergent AEs, treatment -emergent SAEs and AESIs with onset after the star t of 
infusion (Day 1) to Day 169/Early Discontinuation Visit inclusive will be summarized by dose. The placebo 
subjects from each cohort will be combined for the summaries. Other safety parameters, including laboratory 
assessments and vital signs, will be summarized by dose.
Interim Analysis:
The primary analysis will be performed when all subjects in Cohort 3 have completed the Day 85 assessments 
or have been withdrawn from the study. The primary analysis will include all assessments on the subjects prior
to the data cut -off for  the primary analysis. MedImmune personnel will be unblinded to the subject treatment 
assignments from Cohorts 1 to 3 at the primary analysis (Day 85). The data from the primary analysis will not 
be communicated to personnel at the Contract Research Organization (CRO) or investigational sites or to 
enrolled subjects, until all subjects in Cohorts 1 to 3 have completed the study and database lock has been 
achieved .An additional interim analysis will be performed when all subjects in Cohort 4 have completed the 
Day 85 assessments o r have been withdrawn from the study. MedImmune personnel will be unblinded to the 
subject treatment assignment sfrom Cohort 4 for this interim analysis. Study subjects and personnel at the CRO
or investigati onal sites will remain blinded to Cohort 4 data until all subjects in Cohort 4 have completed the 
study and database lock has been achieved. The final analysis on the subjects will be performed w hen all 
subjects have completed the safety follow -up.
CCI
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
5of 98 Template 16.2TABLE OF CONTENTS
PROTOCOL SYNOPSIS ................................ ................................ ................................ 2
LIST OF ABBREVIATION S................................ ................................ ........................ 10
1 INTRODUCTION ................................ ................................ .............................. 13
1.1 Disease Background ................................ ................................ .................. 13
1.1.1 Evidence for the CD40 Pathway  in RA ................................ .............. 14
1.2 MEDI4920 Background ................................ ................................ ............ 15
1.3 Summary  of Nonclinical Experience ................................ ......................... 15
1.4 Summary  of Clinical Experience ................................ ............................... 17
1.5 Rationale for Conducting the Study ................................ ........................... 18
1.6 Potenti al Risks ................................ ................................ .......................... 19
1.7 Research Hypotheses ................................ ................................ ................ 21
1.7.1 Primary Hypothesis ................................ ................................ ........... 21
1.7.2Secondary  Hypothesis ................................ ................................ ....... 21
1.7.3 Exploratory  Hypotheses ................................ ................................ ....22
2 OBJECTIVES AND ENDPO INTS ................................ ................................ .....22
2.1 Object ives................................ ................................ ................................ .22
2.1.1 Primary Object ive................................ ................................ ............. 22
2.1.2 Secondary  Object ives................................ ................................ ........ 22
2.1.3 Exploratory  Objectives ................................ ................................ ......22
2.2 Study  Endpo ints................................ ................................ ........................ 22
2.2.1 Primary Endpo ints................................ ................................ ............. 22
2.2.2 Secondary  Endpo ints................................ ................................ ......... 23
2.2.3 Exploratory  Endpo ints................................ ................................ ....... 23
3 STUDY DESIGN ................................ ................................ ................................ 23
3.1 Descript ion of Study ................................ ................................ ................. 23
3.1.1 Overview………. ................................ ................................ .............. 23
3.1.2 Treatment Regimen ................................ ................................ ........... 25
3.1.3 Dose Escal ation and Cohort Progression ................................ ............ 26
3.2 Rationale for Dose, Populat ion, and Endpo ints................................ .......... 27
3.2.1 Dose Rati onale ................................ ................................ .................. 27
3.2.2 Rationale for Study  Popul ation................................ .......................... 28
3.2.3 Rationale for Endpoints ................................ ................................ .....29
4 MATERIALS AND METHOD S................................ ................................ ......... 30
4.1 Subjects ................................ ................................ ................................ ....30
4.1.1 Number of Subjects ................................ ................................ ........... 30
4.1.2 Inclusio n Cri teria................................ ................................ ............... 30
4.1.3 Exclusio n Cri teria................................ ................................ .............. 32
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
6of 98 Template 16.24.1.4Subject Enrollment and Rando mizat ion................................ ............. 34
4.1.5 Withdrawal fro m the Study ................................ ................................ 35
4.1.6 Discontinuati on of  Invest igational Product ................................ ........ 35
4.1.7 Replacement of Subjects ................................ ................................ ...36
4.1.8 Withdrawal o f Informed Consent for Data and Biological Samples ...36
4.2 Schedule of Study  Procedures ................................ ................................ ...37
4.2.1 Enrollment/Screening Period ................................ ............................. 37
4.2.2 Treatment Period ................................ ................................ ............... 38
4.2.3 Follow-up Peri od................................ ................................ ............... 41
4.3 Descript ion of Study  Procedures ................................ ............................... 42
4.3.1 Medical History , Physical  Examinat ion, Electrocardi ogram , Weight, 
Height, and Vi tal Signs................................ .................... 42
4.3.1.1 Medical History ................................ ............................... 42
4.3.1.2 Physical Examinat ion, Height, and Weight ....................... 42
4.3.1.3 Vital Signs................................ ................................ ....... 43
4.3.1.4 Electrocardiogram ................................ ............................ 43
4.3.2Clinical Laboratory  Tests ................................ ................................ ..44
4.3.3 Pharmacokinet ic Evaluat ion and Methods ................................ ......... 45
4.3.4 Immunogenicit y Evaluat ion and Methods ................................ .......... 45
4.3.5 Biomarker Evaluat ion and Methods ................................ ................... 46
4.3.5.1 Flow Cy tometry ................................ ............................... 46
4.3.5.2 Autoantibody  Panel ................................ .......................... 46
4.3.5.3 Exploratory  Serum  Biomarkers ................................ ........ 46
4.3.5.4 Total  CD40L Levels ................................ ......................... 46
4.3.5.5 Blood Transcri ptom e................................ ........................ 46
4.3.5.6 MBDA Test ................................ ................................ .....47
4.3.6 Disease Evaluat ion and Methods ................................ ....................... 47
4.3.6.1 Tender and Swo llen Joint Counts ................................ .....47
4.3.6.2 Patient’s Gl obal Assessment of Di sease Act ivity.............. 48
4.3.6.3 Physician Glo bal Assessment of Disease Act ivity............ 48
4.3.6.4 Acute -phase Reactants ................................ ..................... 48
4.3.7 Estimate of Vo lume of Blood to Be Collected ................................ ...49
4.4 Study  Suspensio n or Terminat ion................................ .............................. 49
4.5 Invest igational Products ................................ ................................ ............ 50
4.5.1 Ident ity of Invest igational Products ................................ ................... 50
4.5.1.1 Invest igational Product Handling ................................ .....51
4.5.1.2 Invest igational Product Inspect ion................................ ....51
4.5.1.3 Dose Preparation Steps ................................ ..................... 51
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
7of 98 Template 16.24.5.1.4 Reconst itution Procedure ................................................. 52
4.5.1.5 Preparati on of  Intravenous Dose ....................................... 52
4.5.1.6 Intravenous Administration .............................................. 53
4.5.1.7 Treatment Administration ................................................ 54
4.5.1.8 Moni toring of Dose Administration .................................. 54
4.5.1.9 Reporting Product Complaints ......................................... 55
4.5.2 Addit ional Study  Medicat ions........................................................... 55
4.5.2.1 Background Medicat ions for RA ...................................... 55
4.5.3 Labeling………. ................................................................................ 57
4.5.4 Storage………. ................................................................................. 57
4.5.5 Treatment Compliance ...................................................................... 57
4.5.6 Accountabilit y................................................................................... 57
4.6 Treatment Assignment and Blinding ......................................................... 57
4.6.1 Methods for Assigning Treatment Groups ......................................... 57
4.6.2 Methods for Ensuring Blinding .......................................................... 58
4.6.3 Methods for Unblinding .................................................................... 58
4.6.3.1 Unblinding in the Event of a Medical Emergency ............. 58
4.6.4 Unblinding for Interim Analysis Purposes ......................................... 59
4.7 Restrictions During the Study  and Conco mitant Treatm ent(s) ................... 59
4.7.1 Permi tted Concomitant Medications .................................................. 59
4.7.2 Prohibited Con comitant Medi cations................................................. 59
4.8 Statistical Evaluat ion................................................................................. 60
4.8.1 General Considerations ..................................................................... 60
4.8.2 Sample Si ze and Power Calculations ................................................. 61
4.8.3 Exploratory  Efficacy  Analyses .......................................................... 61
4.8.3.1 ..................................................................... 61
4.8.3.2 ……. ................................................................... 62
4.8.3.3 .................................... 62
4.8.4 Safety………. ................................................................................... 62
4.8.4.1 Analysis of Adverse Events .............................................. 62
4.8.4.2 Analysis of Clinical Laboratory  Parameters ...................... 63
4.8.4.3 Other Safet y and Tol erabilit y Endpo ints........................... 63
4.8.5 Analysis of Immunogenicit y/Pharmacokinet ics................................. 63
4.8.6 Interim Analysis ................................................................................ 63
5 ASSESSMENT OF SAFETY .............................................................................. 64
5.1 Definition of Adverse Events .................................................................... 64
5.2 Definit ion of Serious Adverse Events ........................................................ 65
5.3 Definit ion of Adverse Events of Special Interest ....................................... 65
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
8of 98 Template 16.25.4 Recording of Adverse Events ................................ ................................ ....66
5.4.1 Time Period for Collect ion of Adverse Events ................................ ...66
5.4.2 Follow-up of  Unreso lved Adverse Events ................................ .......... 66
5.5 Reporting of Serious Adverse Events ................................ ........................ 67
5.6 Other Events Requiring Immediate Reporting ................................ ........... 67
5.6.1 Overdose………. ................................ ................................ .............. 67
5.6.2 Hepati c Funct ion Abnormalit y................................ .......................... 68
5.6.3 Pregnancy………. ................................ ................................ ............. 68
5.6.3.1 Maternal Exposure ................................ ........................... 68
6 STUDY AND DATA MANAG EMENT ................................ ............................. 69
6.1 Training of Study  Site Personnel ................................ ............................... 69
6.2 Moni toring of the Study ................................ ................................ ............ 69
6.2.1 Source Data ................................ ................................ ....................... 70
6.2.2 Study  Agreements ................................ ................................ ............. 70
6.2.3 Archiving of Study  Docum ents................................ .......................... 70
6.3 Study  Timetable and End of Study ................................ ............................ 70
6.4 Data Management ................................ ................................ ..................... 70
6.5 Medical Monitor Coverage ................................ ................................ ........ 71
7 ETHICAL AND REGULATO RY REQUIREMENTS ................................ ........ 71
7.1 Ethical Conduct of the Study ................................ ................................ .....71
7.2 Subject Data Protection ................................ ................................ ............. 71
7.3 Ethics and Regulatory  Review ................................ ................................ ...72
7.4 Inform ed Consent ................................ ................................ ...................... 73
7.5 Changes to the Protocol and Informed Consent Form ................................ 73
7.6 Audits and Inspect ions................................ ................................ .............. 74
8 REFERENCES ................................ ................................ ................................ ...75
9 CHANGES TO THE PROTO COL ................................ ................................ ......79
10 APPENDICES ................................ ................................ ................................ ....83
10.1 Appendix 1 -Signatures ................................ ................................ ............ 83
10.2 Appendix 2 -Addit ional Safet y Guidance ................................ ................. 86
10.3 Appendix 3 -National Inst itute of Allergy and Infectious Diseases and Food 
Allergy  and Anaphylaxis Network Guidance for Anaphylaxis 
Diagnosis ................................ ................................ ....................... 90
10.4 Appendix 4 -Actions Required in Cases of Increases in Liver Bi ochemistry  
and Evaluat ion of Hy’s Law ................................ ........................... 91
10.4.1 Introduction ................................ ................................ ..................... 91
10.4.2 Definit ions................................ ................................ ...................... 91
10.4.2.1 Potenti al Hy’s Law ................................ ............ 91
10.4.2.2 Hy’s Law ................................ ........................... 91
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
9of 98 Template 16.210.4.2.3 Ident ification of Potential Hy’s Law Cases ......... 92
10.4.3 Follow-up………. ................................ ................................ ........... 93
10.4.3.1 Potenti al Hy’s Law Cri teria Not Met .................. 93
10.4.3.2 Potenti al Hy’s Law Cri teria Met ......................... 93
10.4.4 Review and Assessment of Potent ial Hy’s Law Cases ..................... 93
10.4.5 Actions Required When Potential Hy’s Law Criteria Are Met Before 
and After Starting Study  Treatm ent................................ ..94
10.4.6 Actions Required for Repeat Episodes of Potential Hy’s Law .......... 95
10.4.7 References………. ................................ ................................ .......... 96
10.5 Appendix 5 –Diagnosis of a P otenti al Thromboembolic Event ................. 97
10.5.1 Clinical Probabilit y Score of  Deep Vein Thro mbosis -Wells 
Criteria................................ ................................ ............. 97
10.5.2 Clinical Probabilit y Score of  Pulm onary  Embolism -Wells Criteria 98
LIST OF IN -TEXT TABLES
Table 3.1.2 -1 Invest igational Product Dose and Treatment Regimen ...................... 26
Table 4.1.2 -1 Highly Effective Methods of Contraception for Females of 
Childbearing Potential ................................ ................................ ......32
Table 4.2.1 -1 Schedule of Screening Procedures ................................ .................... 37
Table 4.2.2 -1 Schedule of Treatment Period Study  Procedures ............................... 39
Table 4.2.3 -1 Schedule of Fo llow-up Procedures ................................ .................... 41
Table 4.3.7 -1 Estimate of Blood Volume to Be Collected ................................ ....... 49
Table 4.5.1 -1 Ident ification of Invest igational Products ................................ .......... 50
Table 4.5.1.5 -1 MEDI4920 Dose Preparation for IV Infusio n with an IV Infusi on 
Pump................................ ................................ ................................ 52
Table 4.5.1.5 -2 Placebo Dose Preparation for IV Infusio n with an IV Infusio n Pum p53
Table 4.5.1.6 -1 Intravenous Administration of Invest igational Product ...................... 54
LIST OF IN -TEXT FIGURES
Figure 3.1.1 -1 Study  Flow Diagram ................................ ................................ ......... 25
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
10of 98 Template 16.2LIST OF ABBREVIATION S
Abbreviation or 
Specialized TermDefinition
ACPA anti-cyclic citrullinated peptide antibody
ACR American College of Rheumatology
ADA anti-drug antibody
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT Alanine aminotransferase
ANA anti-nuclear antibody
AST aspartate aminotransferase 
AUC area under the concentration -time curve 
BP blood pressure
CD40L CD40 ligand
CDAI Clinical Disease Activity Index
cDMARD conventional disease -modifying anti -rheumatic drug
CI confidence interval
Cmax maximum concentration 
CMV cytomegalovirus
COPD chronic obstructive pulmonary d isease
CRO Contract Research Organization
CRP C-reactive protein
CTLA -4 cytotoxic T ly mphocy te antigen -4 
CTPA computerized tomographic pulmonary angiography
DAS28 CRP Disease Activity Score in 28 joints using C -reactive protein 
DEC Dose Escalation Committee
DNA deoxyribonucleic acid
DMARD disease -modifying anti -rheumatic drug
DVT deep vein thrombosis
DZP dapirolizumab pegol
EBV Epstein -Barr virus
EDC electronic data capture
ECG electrocardiogram
eCRF electronic case report form
EDV Early  Discontinuation Visit
Emax maximum effect attributable to the drug
ESR erythrocy te sedimentation rate
FAAN Food Allergy and Anaphy laxis Network
FTIH first time in human 
GCP Good Clinical Practice
GH general health
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
11of 98 Template 16.2Abbreviation or 
Specialized TermDefinition
GLP Good Laboratory Practice
HbcAb hepatitis B core antibody
HbsAb hepatitis B surface antibody
HbsAg hepatitis B surface antigen
HED Human Equivalent Dose
HSA human serum albumin 
HSV herpes simplex virus
HIV Human Immunodeficiency Virus
HL Hy’s Law
ICF Informed Consent Form
ICH International Council for Harmonisation
IGRA interferon -gamma release assay
IEC Independent Ethics Committee
Ig immunoglobulin
IL interleukin
IRB Institutio nal Review Board
ITT intent-to-treat
IV intravenous
IXRS interactive voice/web response system 
JAK Janus kinase
KLH keyhole limpet hemocyanin
LFT liver function test
mAb monoclonal antibody
MAD multiple a scending dose
MCP -Mod multiple comparison procedure with modeling techniques
MBDA multi-biomarker disease activity
MedDRA Medical Dictionary for Regulatory Activities
MDGA Physician’s Global Assessment
MOA mechanism of action
MTX methotrexate
NIAIDs Natio nal Institute of Allergy and Infectious Diseases 
NOAEL no observed adverse effect level 
NSAID nonsteroidal anti -inflammatory drug
PCR polymerase chain reaction
PD pharmacodynamics
PE pulmo nary embolism
PFA platelet function analyzer
PGA Patient’s Global Assessment
PK pharmacokinetics
PT preferred term
Q2W once ever y 2 weeks
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
12of 98 Template 16.2Abbreviation or 
Specialized TermDefinition
RA rheumatoid arthritis
RBC red blood cell
RF rheumatoid factor
RNA ribonucleic acid
SAD single ascending dose
SAE serious adverse event
SC subcutaneous
sCD40L soluble CD40L
SID subject identification
SJC swollen joint count
SLE systemic lupus erythematous
SOC system organ class
TAT thrombin -antithrombin complex
TB Tuberculosis
TBL total bilirubin
TDAR T-cell-dependent antibody response
TEAE treatment -emergent adverse event 
TESAE treatment -emergent serious adverse event
TJC tender joint count
Tn3an engineered form of the third f ibronectin type III protein domain from human 
Tenascin -C
TNF tumor necrosis factor
TNF α tumor necrosis factor alpha
ULN upper limit of normal
US FDA United States Food and Drug Administration
VAS visual analogue scale
V/Q ventilatio n-perfusion
VZ varicella zoster
WBC white blood cell
w/v weight/volume 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
13of 98 Template 16.21INTRODUCTION
1.1 Disease Background
Rheumatoid arthrit is (RA) is a chronic systemic inflammatory disease that is associated with 
significant m orbidi ty and m ortali ty. The disease is characterized by  inflammat ion of the 
synovial jo ints that can result in pain, swelling, and jo int dam age wi th secondary  deformity 
and progressive disabilit y. Worldwide, the prevalence of RA is est imated to be between 0.6% 
and 1.1% with variations across geographical regio ns. The incidence is 2 -3 times higher in 
wom en than in men with a peak age of onset between 35 and 55 y ears of 
age(Symmo ns,2002 ). Uncontrolled act ive RA causes jo int dam age, disabilit y, decreased 
qualit y of life, com orbidi ties incl uding cardi ovascul ar disease and osteoporosis, and reduced 
life expectancy ( Wong et al, 2001 ).
The immunopathology  of RA is com plex even from relat ively early in the clinical course of 
disease ( Tarner et al , 200 6; van Baarsen et al , 2013 ) and B cells are generally accepted to 
contribute to the pathophysio logy of RA. Defect ive central and peripheral B -cell tol erance 
checkpoints in RA result in accumulat ion of autoreactive B cells ( Bugatti  et al , 2014),and 
depletion of CD20 posit ive B cells wit h rituximab results in clinical improvement in a subset 
of patients. Approximately 80% of patients wi th RA have detectabl e levels of rheumatoid 
factors (RF s),which are ant ibodies of any isot ype ( immunoglobul in [Ig] M, IgG, IgE) against 
the Fc porti on of  IgG. The m ajority of patients wi th RA also have detectable levels of 
anti-cycli c citrullinated pepti de ant ibodies (ACPAs). Indeed, the presence of RF or ACPA is 
included in the American College of Rheumatology (ACR) 2010 diagnostic criteria for RA.
There are 3 main drug classes co mmo nly used in the treatment of RA: 1) nonsteroidal 
anti-inflammatory  drugs (NSAIDs), 2) corticosteroids, which are mainly used as palliat ive 
therapy , and 3) di sease -modifying anti-rheumat ic drugs (DMARDs), used to control disease 
activit y and prevent structural jo int dam age. Two main classes of DMARDs are available for 
the treatment of RA: convent ional disease -modifying anti -rheumat ic drugs (cDMARDs) 
(such as methotrexate [MTX] , sulfasalazine, leflunomide, and hydroxy chloroquine) and 
biologic DMARDs (such as tumor necrosis factor [TNF] -inhibitors ).MTX is the most 
commo nly used DMARD for the treatment of moderate and severe RA (Maetzel etal,1998 ); 
however, many pat ients fail to achieve an adequate or sustained response to MTX alone 
(Galindo -Rodriguez et al, 1999 ). To improve efficacy , MTX i s being combined with newer 
biologic agents targeting va rious com ponents of the immune system, which has induced a 
step-change in the management and treatment of patients with RA. Such therapies include 
anti-TNF alpha (TNFα) agents (etanercept, infliximab, adalimumab, certolizumab and 
golimumab) as well as newe r agents targeting different compart ments of the immune system, 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
14of 98 Template 16.2such as B cells, cytotoxic T -lymphocy te ant igen-4 (CTLA -4) (abatacept), and interleukin 
(IL)-6 receptors (tocilizumab); newer oral co mpounds such as inhibitors of Janus kinase 
(JAK; tofacit inib) have also been introduced. These agents are effect ive at improving the 
signs and symptoms and at slowing or arresting structural damage in pat ients with RA 
(Klareskog et al, 2004 ; Singh et al, 2009 ).
Despite the availabilit y of these bi ological therapeuti c agents for the treatment of RA, nearly  
one third of pat ients fail to achieve the ACR 20% improvement 
criteria (Weinblatt etal,2003 ), and only a minorit y of patients achieve clinical remissio n 
(Listing et al, 2006 ). Thus there is a need for new effective treatments to reduce disease 
activit y in pat ients with RA.
1.1.1 Evidence for the CD40 Pathway in RA
Geno me-wide associ ation studi es have i dentified a comm on variant in the CD40 locus that 
increases the risk of RA ( Scheinman, 2013 ). The CD40 receptor is a m ember of the TNF 
family o f receptors expressed on the plasma membran e of antigen-stimulated B cells, 
macrophage, and dendrit ic cells (Croft et al , 2013 ). The CD40 receptor funct ions to provide a 
co-stimulatory  signal for B cells, which have bound antigen. The cognate ligand for CD40 is 
CD40 ligand (CD40L) (also known as CD154) that is expressed on the plasma membrane of 
T cells and other cell t ypes, including platelets. Cell contact -dependent interaction 
between CD40L and CD4 0 is crit ical for the developm ent of a com prehensive immune 
response (Ford et al , 2014 ). The RA risk allele is a gain -of-funct ion allele that increases the 
amount of CD40 on the surface of primary  human B lymphocy te cells and probably  other 
cell t ypes ( Li et al , 2013 ). The expressio n of CD40L on CD4+ T helper cells is also 
increased in pat ients with active RA co mpared to those in clinical remissio n or healthy 
control s (Berner et al, 2000 ; Zhang etal, 2013 ). Taken together, these observat ions suggest 
that inhibit ion of the CD40L/CD40 pathway may be beneficial in RA.
The bio logy of the CD40/CD40L pathway is not completely  understood. Interacti on between 
CD40L and CD40 results in pro teolytic cleavage of membrane CD40L that generates a 
soluble fragment ( sCD40 L) retaining the abilit y to bind to CD40 (Alaaeddine etal,2012). 
The concentrations of sCD40L are increased in several autoimmune diseases including RA, 
systemic lupus ery thematosus (SLE), and Sjogren’s syndro me. The bio logical significance of 
this is unknown as sCD40L may simply  reflect increased activation of platelet and T cells 
resul ting in release of sCD40L. Others have proposed that sC D40L may have a counter -
regul atory  immunosuppressive rol e, at l east in a cancer setting ( Huang et al, 2012 ).In 
addition, CD40L can bind to receptors other than CD40, namely , the integrins αIIbβ3, α5β1, 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
15of 98 Template 16.2and αMβ2, and a va riety of biological functions for these interactions have been proposed 
(Alaaeddine et al, 2011 ). 
In previous early  clinical studi es, the m onocl onal ant i-CD40L IgG1 ant ibody , known as 
BG9588 showed signs of potentia l efficacy  in pat ients with SLE and immune 
thrombocy topenic purpura ; however, the clinical development of this agent was halted due to 
clinically significant thromboembo lic events ( Boumpas et al, 2003 ;Kuwana 2004 ).
Furtherm ore, the clinical program of another anti -CD40L monoclonal antibody  (mAb ), 
IDEC -131 mAb (which was under evaluation in Phase 1and 2trials), was curtailed 
subsequent to the reporting of a thromboembo lic event in Crohn’s disease. These mAbs were 
Fc enabled, and subsequent nonclinical studi es identified that platelet activat ion due to 
binding of Fc receptor by  immune co mplexes of ant i-CD40L and so luble CD40L was the 
likely  mechanism underlying the assoc iation between ant i-CD40L exposure and 
thrombosis (Langer etal,2005 ;Robles -Carrillo, 2010 ). Recently, UCB reported data on 
CDP7657 (Dapi rolizumab pego l [DZP]) , ananti-CD40 Lantibody  lacking an Fc domain, in 
non-human primates (Shock etal,2015 ) and in healt hy volunteers and pat ients with SLE 
(Tocoian, et al, 2015 ;Chamberlain et al, 2015 ). Single and m ultiple administrations of DZP
over 12 weeks in pat ients with mild to m oderate SLE were well tolerated ,and the safet y
profile supports further development. Exploratory  analyses s how greater improvement in 
clinical measures of disease activit y in the DZP group vs placebo ( Chamberlain et al,2015 ).
1.2 MEDI4920 Background
MEDI 4920 is briefly described below. Refer to the current Inves tigator’s B rochure for 
details.
MEDI4920 is a CD40L antagonist that comprises two identical Tn3 modules fused to human 
serum  albumin (HSA). Each Tn3 is an engineered form of the third fibronect in type III 
protein domain fro m human Tenascin C. Polyglycine linkers jo inthe two Tn3 dom ains and 
the second Tn3 domain to the HSA protein. Each Tn3 binds specifically to human CD40L 
and inhibit s its interacti on wi th human CD40. 
1.3 Summary of Nonclinical Experience
MEDI4920 has been evaluated in several toxico logy studi es (please refer to Invest igator’s 
Brochure for more detailed informat ion). The cynomo lgus mo nkey was selected specifically 
for use in these studies as MEDI4920 binds to and neutralizes the pharmaco logical activit y of 
human and cyno molgus monkey CD40L. Human ant i-CD40L m olecules do not cross -react 
with murine CD40L.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
16of 98 Template 16.2Several repeat -dose studies (maximum weekly dosing duration of 6 months) and one single 
dose study  were conducted to evaluate the safet y, pharmacokinet ics (PK), and 
pharmacodynamics (PD) of CD40L inhibit ion by intravenous (IV) and/or subcutaneous (SC) 
administration of MEDI4920 or its parent mo lecule. 
The no observed adverse effect levels (NOAELs) for repeat -dose studies were the highest 
doses tested for most of the studies: 150 mg/kg weekly IV or SC and 300 m g/kg weekly IV 
for the 5 -week studies; 250 mg/kg weekly SC for the 6 -month study . The NOAEL for the 
single -dose study  was 600 m g/kg IV. 
Weekly IV administration of 150 or 300 mg/kg MEDI4920 to sexually mature cyno molgus 
monkeys for 6 months resulted in early euthanasia of one animal at 150 mg/kg/dose on 
Day 92 associated with declining clinical condit ion, adverse clinical patho logy changes, and 
microscopic evidence o f inflammatory cell infiltrates in mult iple tissues. In addit ion,one 
animal dosed at 300 m g/kg/dose had enlarged spleen wit h nodular and abnormal appearance 
at scheduled necropsy  onDay 192. Microscopi cally , increased am ounts of inflammatory  cell 
infiltrates in mult iple organs and tissues were present in this animal and a systemic 
opportun istic fungal infect ion was detected; this was considered secondary  to the 
pharmaco logy of MEDI4920 . Therefore, no NOAEL was established for IV dosing in the 
6-month study . 
There were no MEDI4920 -related clinical observa tions in any o f the other animals. In 
addition, there were no MEDI4920 -related changes in body  weight, food consumption, 
ophthalmo logy, electrocardi ology or blood pressure (BP) in any animals. There were no 
changes in total serum IgM, IgG, IgE, or IgA levels that were considered to be 
MEDI49 20-related. 
There were no MEDI4920 -related effects on female reproductive endpo ints, including 
menstrual cycling, organ weights, or microscopic pathology . There was no evidence of a 
MEDI4920 -related effect on male reproductive parameters, based on an over all weight of  
evidence analysis of testicular volume, sperm concentration and mot ility, sperm morpho logy, 
organ wei ghts and histopathology  of reproductive and accessory  sex organs . 
Clinical patho logy eval uations, including hematology , clinical chemistry , 
urinalysis, thrombin -antithrombin co mplex (TAT), D -dimer, and platelet funct ion analyzer 
(PFA) -100 collagen/epinephrine closure times were performed on all animals in all studies. 
There were no MEDI4920 -related adverse findings for any o f these parameters in the single 
dose Good Laboratory  Practi ce (GLP )(1468 -036), the 1-month GLP (1468 -035), the 
6-month GLP (20048035), or the non-GLP (1468 -027) studies. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
17of 98 Template 16.2Any addit ional observat ions noted for hematology , clinical chemis try, or urinalysis 
param eters in the other studies were of small magnitude and transient in nature or were 
within the normal range for naive non -human primates.
In all of the repeat -dose studies, observed maximum concentration (C max), observed 
minimum conc entrati on (C trough ), and area under the concentration -time curve (AUC) 
increased dose proportionally across the dose range after the first and last dose. 
Bioavailabilit y with SC dosing ranged between 73% to 83% in the repeat -dose studies. PD 
sample analysi s showed a dose -dependent increase in the levels of sCD40L, consistent with 
the expected accumulat ion of sCD40L:MEDI4920 complexes.
Immunologic changes included dose -dependent decreases in CD20+ B-lymphocy tes (fl ow 
cytometry) and decreases in T -cell-depen dent ant ibody  responses (TDARs); (anti-keyho le 
limpet hemocyanin [KLH ]IgG and IgM) . 
1.4 Summary of Clinical Experience
As of 25Aug2015 (cutoff date for D5100C00001 Cohort 6 interim analysis), a total of 
46healt hy volunteers have received single IV doses of MEDI4920 over the dose range 3 mg 
to 1000 m g in Study D5100C00001.
Study  D5100C00001 isa Phase 1, randomized, blinded, placebo -controlled, single ascending 
dose (SAD) study  to eval uate the safet y and tol erabili ty of single -ascending IV doses of 
MEDI4920 i n healt hy adult male subjects and healthy  adul t female subjects of 
non-childbearing potential. In addi tion to assessing safet y and tol erabili ty, the study  also 
characterized the PK o f MEDI4920, assessed ant i-drug antibody  (ADA) to MEDI4920, and 
evaluated t he effect of MEDI4920 on TDAR after administration of the KLH ant igen. The 
study  was conducted at one site in the United Kingdom. A total of up to 56 subjects were 
planned for randomization wit hin this study : 3 subjects were randomized in a 2:1 ratio for 
each of Cohorts 1 and 2 (3 and 10 mg MEDI4920, respectively  or pl acebo) and 10 subjects 
each rando mized in a 4:1 rati o for Cohorts 3 to 7 (30, 100, 300 , 1000, and 3000 mg
MEDI4920, respectively, or placebo).
When all subjects in Cohort 5 completed Day  43assessments, a first interim analysis was
conducted to evaluate the safet y and tol erabili ty ofMEDI4920, PK, ADA, and the level o f 
inhibit ion of the TDAR in Cohorts 1-5. With respect to safet y, there were n o withdrawals 
from the study , and one serious adverse event (SAE) of fractured t ibiawas reported in the 
placebo arm . Adverse events (AEs) were generally minor and balanced across placebo and 
MEDI4920 dose groups . One case of herpes z oster reacti vation (shingles) was reported in the 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
18of 98 Template 16.230 m g dose group (Grade 2, start date Day 79). There were no deaths, no reports of 
thromboembo lic events , no severe hypersensit ivity or severe infection events, and no
concerns from the laboratory  assessment of platelet funct ion and coagulation . PK parameters 
(Cmax and AUC) increased in a dose -proporti onal fashi on, with a half -life o f 
approximately 8days for the 300 mg IV dose. Between 50% to 100% of subjects in 
Cohorts 1 to 4 developed ADAs at at least one time point after dosing, whereas only 3 of 
8subjects in Cohort 5 d eveloped ADAs after dosing. The ADA posit ivesubjects had faster 
clearance and redu ced observed MEDI4920 exposure. According to the pre -specified dose 
escalat ion criteria, as TDAR inhibit ion was < 75% vs placebo and no safet y concerns were 
observed, Cohort 6 (1000 mg dose) was init iated. An a dditional 10 subjects were randomized 
in a 4:1 rati oto receive eit her 1000 mg MEDI4920 or placebo . 
When all subjects in Cohort 6 completed Day  43 assessments, a second interim analysis was 
conducted to evaluate the sa fety and tol erabili ty of MEDI4920, PK, ADA, and the level of 
inhib ition of the TDAR in Cohorts 1 -6, in order to evaluate the requirement for
Cohort 7(3000 mg).The safet y profile rem ained consistent with the safet y profile observed 
at the first interim an alysis, wi th no deaths, seri ous or severe AEs, thromboembo lic events , 
severe hypersensit ivity or severe infect ion events ,and no concerns fro m the laboratory  
assessment of platelet funct ion and coagulation . No subjects in Cohort 6 (1000 mg) were 
positive for ADAs up to Day  29, which was the last available ADA time point in Cohort 6 
prior to interim assessments. 
After the second interim analysis, TDAR inhibit ion was observed in a dose -dependent 
manner. A dose response analysis at Day  43 of  the dose cohorts up to and including 1000 mg 
demonstrated a stati stically significant linear dose response (p=0.003) with the 1000 mg 
dose observing a 77% inhibit ion of the TDAR IgG response compared to 
placebo (95% confidence intervals [CIs]: 41%, 91%).
1.5 Rationale for Co nducting the Stud y
MEDI4920 is being developed for the treatment of B -cell dependent autoimmune diseases. 
The current study  is desi gned to characteri ze the safet y, tolerabilit y, PK, bio markers, 
immunogenicit y, and clinical  response of m ultiple doses of MEDI4920 in subjects with 
moderate to severe RA.
The results from this study  will form  the basis for decisio ns regarding appropriate repeat 
dosing strategies of MEDI4920 for future studies in subjects with RA and/or other 
autoimmune condit ions.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
19of 98 Template 16.21.6 Potential R isks
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with I nternat ional Conference on Harmonisat ion 
(ICH)/Good Clinical Practice (GCP) , and applicable regulatory  requirements .
Based on clinical data from Cohorts 1 -6 of the SAD study, there are no ident ified risks for
humans associated with MEDI4920 . Potenti al risks based on the mechanism of act ion 
(MOA) of MEDI4920 and mit igation plans included in the protocol are sum marized below.
Anaphylaxis and Serious Hypersensitivity Reactions 
No severe or serious hypersensit ivity react ions have been observed with MEDI4920 at doses 
up to 1000 mgin the SAD study . 
In the current study , subjects will be excluded from participat ionif they have had a history  of 
a severe allergic reaction to any  com ponent of the investigational product formulat ion or to 
any other bio logic therapy .The ri sk of hypersensit ivity react ions is consi dered m aximal  after 
the first two IV administration sof MEDI4920 (Days 1 and 15). To m onitor for infusio n 
and/or hy persensi tivity react ions, subjects will be in a clinical trial facilit y and closely 
monitored for 4 hours after the end of the infusio n for the first two doses (Day s1 and 15). 
Doses will be adminis tered by IV infusio n over minimum t imes o f 30 minutes for the 75 mg 
dose, 60 minutes for the 500 mg dose , 90minutes for the 1000 mg dose, and 90 minutes for 
the 1500 m g dose. The i nfusio n will be discont inued if there is evidence of infusio n react ion 
and supportive treatment may  be inst ituted. Guidelines for monitoring relevant AEs
enco mpassing hypersensit ivity, angioedema and anaphylaxis and for manag ingacute 
anaphylactic shock and minor allergic episodes will be in place at investigat ional sites. Study  
sites will include facilit ies and expertise for emergency care/resuscitat ion, including access to 
hospi tal and intensive care unit. 
Serious and /orOpportunistic Infection s
Nosevere or serious infect ions have been observed in the first time in human ( FTIH )SAD 
study . One case of herpes zoster reactivat ion was reported in a subject receiving 30 mg 
MEDI4920. 
Weekly IV administration of 150 or 300 mg/kg MEDI4920 to sexually mature cyno molgus 
monkeys for 6 m onths resul ted in an opportunistic fungal infect ion in one animal treated with 
MEDI4920 300mg/kgIV, and changes suggest ing potential systemic infect ion were 
observed in another animal treated with MEDI4920 150mg/kg (see Section 1.3).
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
20of 98 Template 16.2Measures taken in the current study  to minimize the risk of immunosuppressio n-related 
infect ions include the fo llowing:
•During screening, subjects will be excluded from the study  if they  have had a recent 
(within 12 m onths) or acti ve hepat itis A infect ion; if they test posit ive or have been 
treated for hepatit is B, hepat itis C, or human immunodeficiency virus (HIV) infection; if 
they have evidence of act ive or untreated latent tuberculosis (TB); if they have a recent 
history  (last 1 2 months) of recurrent herpes z oster and/or opportunist ic infect ion; and/or 
if they are taking immunosuppressant medicat ion (see exclusio ncriteria in Sect ion 4.1.3
and prohibited conco mitant medications in Sect ion 4.7.2 ).
•Subjects will not be allowed to receive live (attenuated) vaccine within the 4 weeks prior 
to dosing or during the study  until  the end of follo w-up. 
•Clinical assessments for signs o f infect ion will be performed at each study  visit. Subjects 
will be given instructions on potential signs of infection and instructed to contact 
investigator if they  have signs or symptom s of an infect ion. Bl ood sam ples f or serol ogy 
and viral po lymerase chain reaction (PCR )will be collected at screening and stored to 
assess new vs reactivation o f Epstein -Barr virus (EBV) and cy tomegalovirus (CMV) in 
case an EBV or CMV infect ion is reported as an AE during the study.
Unknown C onsequences of Exposure in Utero
No embry o-fetal studies have been conducted to date . 
This study  requi res all  female subjects of childbearing potential to use at least one highly 
effect ive method of contraception fro m the time of screening up through at least 6 months 
after the final dose of investigational product. The acceptable methods of contraception a re 
described in Section 4.1.2 .
In addit ion, the invest igator must inform the subjects about the risks involved with some o f 
the background medicat ions used in RA and accepted i n the current study  (eg,MTX or 
leflunomide) as these agents are known to have potential deleterious effects on conception, 
pregnancy and fetalhealt h(see Section 4.1.2 ).
The requi rement for adherence with contraceptive guidance in the protocol  and screening for 
pregnancy (serum orurine) will be mo nitored throughout the duration of the study .
Thrombotic and Embolic Events
Previous clinical trials with ant i-CD40L mAbs that were Fc enabled demo nstrated increased 
incidence of thromboembo lic events , and subsequent nonclinical studies ident ified that 
platelet activat ion due to binding of Fc receptor by immune co mplexof anti-CD4 0L and 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
21of 98 Template 16.2soluble CD40L was the likely mechanism underlying the associat ion between ant i-CD40L 
exposure and thrombosis. MEDI4920 was engineered to lack Fc fragment. 
No thromboembo lic events have been reported in animal  studi es and in the human SAD 
study  withMEDI4920 .
To minimize the risk of thromboembo lic events in the current study, subjects will be 
excluded fro m participat ion if they have a medical history  of confirmed venous 
thromboembo lism or arteri al thrombosi s or if they have significant clinical and m olecular 
risk factors for thromboembo lic events or arteri al thrombosi s. In addi tion, any subjects wi th a 
clinically significant abnormal coagulat ion panel at screening will be excluded fro m this 
study  (see Section 4.1.3 ).
Thromboembo lic events will be mo nitored by AE evaluat ion and physical examinat ions 
perform ed during the study . If a subject dosed with ME DI4920 experiences a confirmed or 
suspected thromboembo lic event during the evaluation period or follow -up peri od, the dose 
escalat ion will be suspended and the event will be fully evaluated (see Section 3.1.3 for 
additional details) . 
Immune Complex Disease
The potential risk of immune co mplex disease is based on the potential risk known to be 
associ ated wi th foreign proteins and mAbs. The occurrence of ADA could result in immune 
complex disease (wi th manifest ations such as arthralgia, serum -sickness, nephrit is, and 
vasculit is) or altered MEDI4920 levels or activit y. Subjects in clinical studies with 
MEDI4920 will be monitored for the presence o f ADA and for clinical manifestations that 
may be associated with t he formation of specific ant ibodies to MEDI4920.
1.7 Research Hypotheses
1.7.1 Primary Hypothesis
The primary  hypothesis is that m ultiple ascending IV doses up to 1500 mg of MEDI4920 
once every  2 weeks (Q2W) over a 12 -week period will be safe and well -tolerated in s ubjects 
with RA when com pared wi th placebo in combinatio n with MTX or another cDMARD.
1.7.2 Secondary Hypothes is 
A secondary  hypothesis has not been established for this study .
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
22of 98 Template 16.21.7.3 Exploratory Hypotheses
The exploratory  hypotheses are that
 
 
.
2OBJECTIVES AND ENDPOINTS
2.1 Objectives
2.1.1 Primary Objective
To assess the safet y and tol erabilit y of mult iple ascending IV doses of MEDI4920 in subjects 
with adul t-onset RA.
2.1.2 Secondary Objectives
To evaluate the PK and immunogenicit y of MEDI4920 in subjects with adult -onset RA.
2.1.3 Exploratory Objectives
1.
2.
3.
4.
2.2 Study Endpoints
2.2.1 Primary Endpoint s
1.The incidence of AEs and SAEs .
2.The incidence of treatment -emergent AEs of special  interest (AESIs) as follows:
◦ T hrombo tic and embo lic events
◦Hepati c funct ion abnormalit y (meet ing the definit ion of Hy’s Law[HL]; see 
Secti on5.6.2 )
◦ A naphylaxis and serious hypersensit ivity react ions
◦ Infusio n-related reacti ons
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
23of 98 Template 16.2◦ Immu ne com plex disease
◦ S erious and/or opportunistic infect ions (including but not limited to reactivat ion of 
latent viral infection [varicella zoster (VZ) , herpes simplex virus (HSV) , EBV, CMV]
and TB )
3.Vital signs, l aboratory  param eters (including coagulat ion parame ters), electrocardi ogram s 
(ECGs), and physical examinat ions.
2.2.2 Secondary Endpoints
The PK profile , PK param eters, and immunogenicity  of MEDI4920 will be assessed for each 
cohort
2.2.3 Exploratory Endpoint s
1.
2.
3.
4.
5.
3STUDY DESIGN
3.1 Description of Study
3.1.1 Overview
This is a mult icenter , randomized, double -blind (investigator, subject, and sponsor will be 
blinded to treatment assignment), placebo -controlled study  to eval uate the safet y and 
tolerabilit y of mult iple ascending doses (MADs) of MEDI4920 in subjects with adult -onset 
RA (moderate to severe, as defi ned by  DAS28 CRP ≥ 3.2 at screening) with an inadequate 
response to MTX or other cDMARDs or a bio logic anti-TNFα agent. 
The study  is planned to be conducted at approximately 15 sites in 2to 4 countries . A 
maximum of 54eligible subjects are planned for t his study. Approximately 40 subjects will 
be randomized in 3 cohorts to receive either 75 m g (Cohort 1), 500 m g (Cohort 2), or 
1500 mg (Cohort 3)MEDI4920 , or pl acebo once Q2W in combinat ion with MTX or another 
cDMARD for up to 12 weeks .
An addit ional 14 subjects will be rando mized in a 5:2 ratio to an additional cohort (Cohort 4), 
to better characterize the dose (exposure) -response relationship. The selected dose of 
MEDI4920 in Cohort 4 is 1000 mg Q2W.
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
24of 98 Template 16.2Subjects will undergo a screening period of  up to 6 weeks followed by rando mization and 
treatm ent for 12 weeks. Subjects will be fo llowed for an additional 12weeks after the 
treatm ent peri od for saf ety. Each subject will participate in the study  for up to approximately 
30weeks (includes a 6-week screening period, a 12 -week treatment period, and a 12-week 
follow-up period) .
Subjects will receive an IV dose of MEDI4920 or placebo Q2W for up to 12 weeks as 
follows:
•Cohort 1: 75 mg MEDI4920 ( N= 8) or placebo ( N= 2) as a single IV dose admin istered 
over at l east 30minutes Q2W
•Cohort 2: 500 mg MEDI4920 (N = 10) or placebo (N = 4) as a single IV dose 
administered over at least 60 minutes Q2W 
•Cohort 3: 1500 mg MEDI4920 (N = 12) or placebo (N = 4) as a single IV dose 
administered over at least 90 minutes Q2W 
•Cohort 4: 1000 mg MEDI4920 (N = 10) or placebo (N = 4) as a single IV dose 
(administered over at least 90 minutes Q2W ) 
Subjects will be administered invest igational product via IV infusio n using an infusio n pump. 
All subjects willrecei ve a total  of 7 doses of investigat ional product (MEDI4920 or placebo )
during the 12 -week treatment period . Details about dose escalat ion can be found in 
Secti on3.1.3 .
A screening visit(s) will be performed wit hin 6 weeks (42 days) prior to dosing. All subjects 
will receive investigational product on the morning of Day 1. An overnight stay  on Day -1 
prior to administration of invest igational product on Day  1 is recommended but not 
mandatory .If no safety  concerns are i dentified, subjects will be discharged from the study  
site on Day  2 (end of the inpat ient treatm ent peri od) after all study  procedures have b een 
completed. Subj ects in all cohorts will return to the study  site Q2W (Day s 8, 15, 29, 43, 57, 
71, and 85) for invest igational product administration and/or specifi cassessments and blood 
draws, as indicated in Table 4.2.2 -1.
During the treatment period, assessments of RA parameters as well as evaluat ions of safet y, 
tolerabilit y, PK, and immunogenicit y of MEDI4920 will be performed at the time points 
indicated in Table 4.2.2 -1.
Following the final IV infusio n of invest igational product, subjects will return to the study  
site for follow -up visi ts beginning at Week 13 (Day  92) and continuing through Week 24 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
25of 98 Template 16.2(Day  169) to eval uate safet y, tolerabili ty, PK and ADA of MEDI4920 as indicated in 
Table 4.2.3 -1.
A study  flow diagram  is presented in Figure 3.1.1 -1. 
Figure 3.1.1 -1 Study Flow Diagram
Ab = antibody; ADA = anti -drug antibody; D = day; IV = intravenous; PK = pharmacokinetic; Q2W = once 
every 2 weeks
The endpo ints to be m easured in this study  are described in Section2.2.
3.1.2 Treatment Regimen
A maximum of 54 subjects will be randomized in a 4:1 ratio (Cohort 1), in a 5:2 ratio 
(Cohort 2), in a 3:1 ratio (Cohort 3), and in a 5:2 ratio (Cohort 4) to receive eit herMEDI4920 
or placebo as described in Table 3.1.2 -1:

MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
26of 98 Template 16.2Table 3.1.2 -1 Investigational Product Dose and Treatment Regimen
CohortN 
(active:placebo ) Dose Treatment Regimen a
1 4:1 75 mg Single IV dose infused over at least 30 minutes on 
Days 1, 15, 29, 43, 57, 71, and 85
2 5:2 500 mg Single IV dose infused over at least 60 minutes on 
Days 1, 15, 29, 43, 57, 71, and 85
3 3:1 1500 mg Single IV dose infused over at least 90 minutes on 
Days 1, 15, 29, 43, 57, 71, and 85
4 5:2 1000 mg Single IV dose infused over at least 90minutes on Days 
1, 15, 29, 43, 57, 71, and 85 
IV= intravenous; TBD = to be determined. 
aFor Coho rts 1-4, investigational product will be administered via IV infusion using an IV infusion pump .
The timing of administration of invest igational product will be staggered within each cohort 
to allow for review of safet y and tol erabilit y data from  the first group of subjects before 
progression to the next group of subjects .
3.1.3 Dose Escalation and Cohort Progression
Cohorts 1 to 3 will start sequent ially, with escalat ion fro m Cohort 1 to Cohort 2 and Cohort 2 
to Cohort 3 confirmed by a Dose Escalat ion Committee (DEC) comprised o f MedImmune 
study  team  members and the Study  Global Chief Investigator, who will assess in a blinded 
fashio n the safet y/tolerabili ty data af ter the l ast subject in a cohort completes Day 29 
(Week 4) of treatm ent and has AE/safet y laboratory data available at that time point. There 
will be a total of three DEC meet ings during the study; the first DEC meet ingwill only 
review data from Cohort 1 whereas the second DEC meet ing will review cum ulative safet y 
data from  first two dose cohorts being tested to date. The third DEC meet ing will const itute a 
thorough evaluat ion of the cumulative safety  and tol erabili ty data for Cohorts 1 and 2 in 
addition to the data up to Day  85 for Cohort 3. While th is review will not pertain to a dose 
escalat ion, it will  contribute to the deci sion to inst igate Cohort 4 (see below). 
After the last Cohort 3 subject completes the Day  85 (Week 1 2) assessments , the primary  
analysis will be conducted to include safet y, tolerabilit y, PK, ADA, bi omarker, and clinical 
response. Based on the outcome of this analysis, a fourth cohort will be included to better 
understand the dose (exposure) -response relat ionship.
If one or m ore of the fo llowing cri teria are m et, dose escalat ionwill be suspended and the 
event(s) will be fully evaluated:
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
27of 98 Template 16.2•A subject dosed with MEDI4920 experiences a confirmed or suspected thromboembo lic 
event during the evaluat ion peri od or fo llow-up peri od.If the thromboembo lic event is 
initially reported as “sus pected”, because of the unavailabilit y of sufficient inform ation to 
support a definit ive diagnosis at that time, the DEC will re -assess the event when 
complete clinical/laboratory  informat ion is provided by the study  site. A diagnosis 
algorithm (adapted fromWells and Anderson, 2013 ; Section 10.5 [Appendix 5]), is 
recommended to be used for any  case of suspected DVT orPE. This includes clinical 
pre-test probabilit y, D-dimer, and available imaging results. Based on full evaluation of 
the data as well as the diagnosis algorithm, if a thromboembo lic event is ruled out or 
considered unlikely, dose escalat ion can be resumed.
•At least 2 subjects dosed with MEDI4920 in a single cohort experience eitherGrade 3 or 
higher treatment -emergent AE s (TEAEs) of the same ty pe (excluding rheumatoid jo int 
flares) or any  SAE .
•At least 2 subjects dosed with MEDI4920 in a single cohort experience serious infect ions. 
•In addit ion to the above criteria, the DEC may recommend stopping dose escalat ion and 
further evaluat ion of any  significant medical event(s) or confirmed clinically significant 
laboratory  abnorm alities (including coagulat ion tests) that are considered related to 
investigat ional product.
If the DEC suspends the dose escalation and subsequent ly decides to resume dosing at the 
same or higher doses, approval fro m the relevant regul atory  authori ties and Independent 
Ethics Co mmit tees (IE Cs)will be obtained prior to dosing.
3.2 Rationale for Dose, Population, and Endpoints
3.2.1 Dose Rationale
The safet y, tolerabilit y, and PD effects of single IV doses of 3000 mg of MEDI4920 are 
currently being evaluated in healt hy adult vo lunteers in the final cohort of study  
D5100C00001. Data from interim analysis 2 are currently available (see Sect ion 1.4).
To date, there are no dose -limit ing toxicit ies known in humans.
The doses selected in the current study  aim to explore the dose -response relationship for the 
main exploratory  efficacy endpo int in RA while 
testing safet y/tolerabili ty within a well -defined safety  margin predicted based on animal data. 
There i s no precise relat ionship between effic acy in autoimmune diseases and PD models 
(suppressio n of free sCD40L or inhibit ion of TDAR to a m odel neoant igen).
A PK -PD m odel to describe the rel ationship between total sCD40L plasma concentration (as 
a surrogate PD marker of target engagement) and plas ma concentrations of MEDI4920 in 
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
28of 98 Template 16.2healt hy subjects from the SAD study  has been devel oped. The free sCD40L suppressio n after 
repeated dosing was predicted based on this model. The abilit y of MEDI4920 to inhibit 
TDAR has been demo nstrated and quant ified in no n-human primates and also in the FTIH 
SAD study  (D5100C00001). In humans, at single IV dose of 1000 mg (which provides high 
degrees of target engagement in peripheral blood), TDAR inhibit ion was shown to be 
significant; however the dose -response relat ionship may  not have reached a plateau.
The PK -PD m odel predicts that a dose of 75 mg Q2W should maintain an approximately 
95% suppression of free sCD40L throughout the ent ire dosing interval. The safet y margin of 
this dose i s estimated to be approximately  65 fold (method Human Equivalent Dose [HED]), 
which is calculated using the SC NOAEL of 250 mg/ kg weekly  dem onstrated in the 27 -week 
toxicology study  in cyno molgus monkeys. Therefore , a 75 m g dose may  provide som e level 
of clinical response for RA patients whi le maintaining a good safet y profile.
The highest dose level in Cohort 3 ( 1500 mgQ2W ) is also driven by the approximately 
3-fold safet y margin (based on HED) .A significant clinical response in RA pat ients is 
expected with this dose.
An intermediate dose of 500 m g Q2W was selected as the medium dose for the study; this 
dose has a safet y margin o f 10 (based on HED) and is able to inhibit TDAR as shown in the 
SAD study . 
After review of the primary  analysis data, which include dcumulat ive safet y, PK, and 
biomarker data through Cohort 3,Day 85 , the decision was made to explore a fourth dose 
(Cohort 4 , 1000 mg Q2W ), in order to com plete the safet y analysis as well as the dose -
response analysis in the exploratory  efficacy  endpoint. Based on PK -PD m odeling data from 
Cohorts 1 to 3 combined wit h clinical judgement, t he 1000 mg Q2W dose sel ected for 
Cohort 4 is a dose that is expected to resul t in a clinical response comparable tothe 1500 mg 
Q2W dose (highest dose in the study ) but with a larger safet y margin .
3.2.2 Rationale for Study Population
It is acknowl edged that heal thy volunteers coul d also be sel ected as a study  popul ation in a 
Phase 1 MAD study . However, in the current study , subjects wi th RA were selected as the 
study  popul ation for the fo llowing reasons :
•Opportuni ty to test MEDI4920 in a disease where B -cell targeted therapy  (rituximab) is 
known to be clinically  effect ive and where nonclinical evidence suggests the 
CD40L/CD40 pathway is act ive. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
29of 98 Template 16.2•Potenti al for provi ding clinical benefit that can be quant ified in a standardized way to 
subjects wi th RA after 12 weeks of treatment
•It is important to establish the PK and PD in a patient population wit h a well -studi ed 
autoimmune disease such as RA that is characterized by elevated sCD40L compared to 
healt hy vo lunteers.
•Concerns about exposing healt hy volunteers to known and theoretical risks of AEs 
related to MEDI4920 over a 12- week treatment period.
•There i s no well -defined rel ationship between the level of TDAR inhibit ion in healt hy 
volunteers and clinic al efficacy  in pat ients with autoimmune condit ions; thus no relevant 
predi ction of clinical effect iveness can be provided by assessing TDAR response in a 
MAD study  in healthy volunteers. 
•It is important to understand the potentially inhibitory  effect of b ackground 
immuno modulatory  therapy  given in RA (eg, MTX) on ADAs against MEDI4920.
3.2.3 Rationale for Endpoints 
This is the first study  of MEDI4 920in adult subjects with RA and thus it is appropriate that 
the safet y and tol erabili ty of MADs const itute the pr imary endpo int. Addi tionally, the study  
will assess the PK profile and immunogenicit y of MEDI4920 in mult iple doses in 
conjunction with the mechanist ic effect of MEDI4920 as secondary  endpoints .
were 
chosen as key  expl oratory  endpo ints, in order to assess early  signals of clinical efficacy  with 
MEDI4920 in RA that might support further studies in the same indicat ion or in different 
autoimmune condit ions.  and have be en selected due to their high level o f 
standardization and wide use in clinical trials in RA. 
Serum  will be collected to m easure changes in exploratory  biomarkers of disease activit y, 
such as autoantibodies, and bio markers associated with the CD40L pathwa y, including 
biomarkers induced by CD40L signaling. These biomarker measurements will aid in the 
determinat ion of what bio logical pathways are impacted by  MEDI4920 treatment. The 
MBDA panel includes adhesio n molecules, growth factors, cy tokines, m atrix 
metalloproteinases, skeletal proteins, hormones and acute phase proteins. The MBDA panel 
has been demonstrated to be a sensit iveandobject ive measure of clinical disease act ivity, 
with a strong correlat ion to DAS28 CRP.
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
30of 98 Template 16.24MATERIALS AND METHOD S
4.1 Subjects
4.1.1 Number of Subjects
A maximum of 54 subjects with adul t-onset RA (moderate to severe) are planned for this 
study : 10subjects will be randomized in a 4:1 ratio in Cohort 1, 14 subjects will be 
rando mized in a 5:2 ratio in Cohort 2, and 16 subjects will be rando mized in a 3:1 rati o in 
Cohort 3. An addit ional 14 subjects will be randomized in a 5:2 ratio in Cohort 4.
4.1.2 Inclusion Criteria
Subjects m ust m eet all of the fo llowing cri teria.Site staff must contact MedImmune for 
consultation prior to enrolling, rando mizing, or administering invest igational product to any 
subject who deviates from these criteria:
1.Male or female
2.18-70 years ol d (inclusively ) at the time of informed consent
3.Adult -onset RA diagnosed by  European League Against Rheumatism /ACR 2010 cri teria 
(Aletaha et al, 2010 ). Diagnosis of RA should be established at least 6 -months before 
screening.
4.Subjects m ust be treated wi th MTX given orally , SC or intramuscular at a dose of 7.5 -25 
mg/week for at least 12 weeks and thedose must have been stable for at least 6 weeks 
prior to screening . The fo llowing except ion is permitted:
◦MTX -intolerant subjects m ay enter the study  if they  are on cDMARD sfor at least 
12weeks and the dose has been stable for at least 6 weeks prior to screening. 
Combinat ion of two or more cDMARDs is allowed if recommended by nat ional 
guidelines and/or standard medical pract ice. 
5.Subjects who may  have been treated wi th anti-TNFα bio logic agents that were stopped 
for any  reason (l ack of efficacy , safety/tolerabilit y issues or lack of access to drug) at 
least 8 weeks before randomizat ion are eligible. 
6.Subjects treated with an agent wi th a MOA other than ant i-TNF ( eg,anti-IL-6, CTLA -4 
or anti-IL-1) are only eligible if at l east 3monthsor 5 half-lives of the drug ( whichever is 
shorter) have passed between the last dose and the rando mizat ion visit.
7.DAS28 CRP of ≥ 3.2 at screening .
8.At least 4 tender and 4 swollen jo ints assessed at screening and confirmed at 
rando mizat ion out of the 28 joints assessed for DAS28 .
9.Positive for serum  RF and/or ACPA at screening , according to the cent ral laboratory’s 
definit ion of positivity.
10.Age-specific vaccinat ions,as based on local expert recommendations and local standard 
medical pract ice, administered at least 4 weeks pr ior to randomization .
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
31of 98 Template 16.211.Written inform ed consent and any  locally requi red authori zation (eg, data privacy ) 
obtained fro m the subject pri or to performing any  protocol -related procedures, including 
screening evaluat ions.
12.Willing and able to comply with the pro tocol , compl ete study  assessments, and complete 
the study  period.
13.Females of childbearing potential who are or might beco me sexually  active wi th a 
nonsterilized male partner during the duration of study  must use a t leastone highly 
effect ive method of cont raception from screening, and must agree to continue using such 
precauti ons at least 6 m onths after the final dose of invest igational product. It is strongly 
recommended for the male partner of a female subject to also use a male condo m plus 
spermicide thr oughout this period. Cessat ion of contraception after this point should be 
discussed wi th a responsible physician. 
◦Females of childbearing potential are defined as those who are not surgically  sterile 
(ie, surgi cal sterilizati on includes bilateral  tubal  ligation, bilateral  oophorecto my, or 
complete hysterectomy) or those who are not postmenopausal (defined as 12 m onths 
with no m enses wi thout an al ternative medical cause).
◦A highly effect ive method of contraception is defined as one that results in a low 
failure rate (ie, less than 1% per y ear) when used consistent ly and correctly. The 
acceptable methods of contraception are described in Table 4.1.2 -1.
14.Nonsterilized male subjects who are sexually  active wi th a female partner of childbearing 
potenti al must use a condom with spermicide from Day  1 through to the end of the study .
In rel ationship wit h inclusio n criteria 13 and 14, since so me o f the background medicat ions 
used in RA and accepted in the current study  (eg, MTX or l efluno mide) are known to have 
potenti al deleteri ous effects on conception, pregnancy and fetal healt h, the invest igator must 
inform  the subjects about these risks and should manage every case of planne d concepti on or 
pregnancy according to the local medical practice standards. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
32of 98 Template 16.2Table 4.1.2 -1 Highly Effective Methods of Contraception for Females of 
Childbearing Potential
Physical Methods Hormonal Methods
•Intrauterine device (IUD)
•Intrauterine hormone -releasing system (IUS) a
•Bilateral tubal occlusion
•Vasectomized partner b
•Sexual abstinence cCombined (estrogen and progestogen containing 
hormonal contraception)
•Oral (combined pill)
•Injectable
•Transdermal ( patch)
Progestogen -only hormonal contraception associated 
with inhibition of ovulation d
•Injectable
•Implantable
•Intravaginal
aThis is also considered a hormonal method.
bWith appropriate post -vasectomy documentation of surgical success (absence of sperm in ejaculate).
cSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of the study and if it is the preferred and usual lifestyle of the subject.
dProgestog en-only hormonal contraception, where inhibition of ovulation is not the primary mode of action 
(minipill) is not accepted as a highly effective method .
Periodic abst inence, the rhythm method, and the wit hdrawal method are not acceptable 
methods of birth control.
4.1.3 Exclusion Criteria
Any of the fo llowing woul d exclude the subject from participat ion in the study .Site staff 
must contact MedImmune for consultation prior to enrolling, rando mizing, or administering 
investigat ional product to any  subject who devi ates f romthese cri teria:
1.A history  of, or current inflammatory  joint disease other than RA (eg, gout, reactive 
arthri tis, psoriatic arthrit is, seronegative spondyloarthropathy, or Lyme disease) or other 
systemic autoimmune disorder (eg, SLE, inflammatory  bowel  disease, scleroderm a, 
inflammatory  myopathy , mixed connective ti ssue di sease, or other overlapping 
syndro me). Subjects with polymyalgia rheumat ica will be excluded fro m the study .
2.Subjects with a medical history  of confirmed venous thromboembo lism or arteri al
thrombosis .
3.Subjects with risk factors for venous thromboembolism or arteri al thrombosis ( eg,
immobilizati on or m ajor surgery  within 12 weeks before screening), prothrombotic status 
(including but not limited to congenital or inherited deficiency o f antithrombin III, 
protein C, protein S , orconfirmed diagnosis of antiphospho lipid syndro me).
4.Subjects with clinically significant abnormal coagulat ion panel at screening ( including 
but not limited to mult iple and significant shifts in p rothrombin time ratio, activated 
partial thromboplast in time ( D-dimer , etc).In case of doubts in assessing coagulat ion 
abnorm alities as being clinically significant, the investigator may  contact and di scuss 
with the study  medical m onitor. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
33of 98 Template 16.25.RA funct ional class IV, presence o f severe systemic com orbidities (extensive vasculit is, 
pericardi tis, amylo idosis, lympho ma), hemochro matosis, IgG4 -related diseases, 
auto-inflammatory syndromes including Still’s and Felt y’s syndro me.
6.Active or recent history (within the last 10 y ears) of malig nancies (except for non -
melano ma skin cancers and in situ cervical carcinoma ,treated and considered cured ).
7.Pregnancy or lactation.
8.Subjects with recent (within 12 months) or active hepatitis A infect ion as evidenced by  
clinical history  and/or posi tive te st for anti -hepati tis A ant ibodies.
9.Subjects who have a posit ive test for, or have been treated for hepatit is B, hepat itis C, or 
HIV infect ion. Regarding hepat itis B,any of the following would exclude the subject 
from the study : 
◦Subjects posit ive for hep atitis B surface ant igen (HbsAg) 
◦Subjects with hepatit is B virus deoxyribo nucleic acid (DNA) levels > 200 copies/mL 
(quant ified by real -time polymerase chain react ion) in case the subject is posit ive for 
hepat itis B surface antibody (HbsAb) but negat ive for HbsAg. 
◦Positive for hepat itis B core antibody  (HbcAb) 
10.Evidence or history of active or untreated latent TB:
◦Signs or symptoms suggest ive of act ive TB upon medical history or physical 
examinat ion
◦Positivediagnosti c TB test duri ng screening (defined as a positiveinterferon-gamma 
release assay  [IGRA] test for TB at screening).
◦Subjects with an indeterminate IGRA should undergo a repeat test ,and if st ill 
indeterminate ,must be excluded .
11.More than one episo de of herpes zoster and/or opportunist ic infect ionin the last 
12months. 
12.Known history  of severe allergy or reaction to any  com ponent of the invest igational 
product formulat ion or to any  other bi ologic therapy .
13.Any severe cardio vascular, respiratory , end ocrine, gastro -intestinal, hematological, 
neuro logical, psychiatri c, or sy stemic disorder that could impact the evaluation o f safety  
and efficacy  assessments or affect the subject’s abilit y to parti cipate in the study  or the 
subject’s safet y.
14.Any condit ionthat, in the opinio n of the invest igator, would interfere with evaluat ion of 
the invest igational product or interpretation of subject safet y or study resul ts. This 
includes important and extensive jo int pain and swelling not due to RA ( eg,severe 
polyarti cular osteoarthritis involving small jo ints in hands and feet ). Those medical 
condi tions that are only  limited to a sm all number of j oints such as localized osteoarthri tis
(eg, knee, hip, and spine) can be included in the study .
15.Receipt of live (attenuated ) vaccine within the 4 weeks before screening or during the 
study .
16.Last administration o f licensed or experimental bio logic agents used for treatment of RA 
targeting any other mechanism other than direct anti -TNF blockade, ( eg,CTLA -4 and 
anti-IL-6) ≤3months before rando mizat ion; last administration of new oral  com pounds 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
34of 98 Template 16.2targeting any other mechanism s(eg,JAK inhibitors) for treating RA ≤3months before 
rando mizat ion.
17.Previous treatment with any bio logic cell -deplet ing therapy ( eg,rituximab ) for RA or 
anti-CD40/CD40L agents .
18.Concurrent treatment with any bio logic or nonbio logic DMARDs excluding stable 
background MTX or other cDMARDs including stable sulfasalazine, l eflunomide, 
hydroxy chloroquine, azathioprine, cyclosporine ,or D-penicillamine .
19.Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose 
oral prednisone or equivalent within 4weeks pri or to randomizat ion. Concomi tant 
treatm ent wi th oral corti costeroi ds ≤ 10 m g/day predniso ne or equivalent is permitted 
provi ded that the dose is stable for ≥ 4weeks prior to randomizat ionand remains stable 
for the durati on of  the treatm ent peri od.Inhaled or topical corticosteroids given for 
asthma, chronic obstructive pulmo nary disease (COPD) or dermatological condit ions are 
allowed provided doses are stable between screening and Day  85 visi t. 
20.At screening blood tests, any  of the f ollowing: 
◦Aspartate aminotrans ferase (AST) > 2 × upper limit of normal (ULN) 
◦Alanine aminot ransferase (ALT) > 2 × ULN
◦Alkal ine phosphatase (ALP) > 2 × ULN
◦Total  bilirubin (TBL) > 2×ULN 
◦Hem oglobin < 75 g/L 
◦Neutrophils < 1.5 × 109/L
◦Platelets < 100 × 109/L
21.History  of alcohol  or drug abuse within 2 years prior to randomization. 
Subjects may be re -screened only once if they do not meet the eligibilit ycriteria related to 
disease act ivity or previ ous RA m edicat ion wash -out. Subj ects not fulfilling any  of theother
eligibilit ycriteria cannot be re -screened.
4.1.4 Subject Enro llment and Randomization
Study  parti cipat ion begins (ie, a subject is “enro lled”) once written informed consent is 
obtained. Once informed consent is obtained, a subject ident ificat ion (SID) number will be 
assigned by  a central  system  (eg, an interactive voice/web response system [IXRS]), and the 
screening evaluat ions m ay begin to assess study  eligibilit y (inclusio n/exclusio n) cri teria. The 
SID number will be used to ident ify the subject during the screening process and throughout 
study  participati on, if applicable. 
A master log o f all consented subjects will be maintained at the site and will document all 
screening failures (ie, subjects who are consented but do not meet study  eligibilit y criteria 
and/or are not randomized), including the reason(s) for screening failure.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
35of 98 Template 16.24.1.5 Withdrawa l from the Study
Subjects are free to withdraw their consent to partici pate in the study  (invest igational product 
and assessments), at any time without prej udice to further treatment . Subj ects who wi thdraw 
consent will be asked about the reason(s) and the presence of any  AEs. If the subject i s 
willing, the subject will be seen and assessed by the invest igator. All AEs will be fo llowed 
up.If a subject withdraws consent from further participat ion in the study , then no further 
study  visits or data collect ion shoul d take pl ace.
4.1.6 Discontinuation of Investigational Product
An individual subject will not receive any further investigational product if any o f the 
following occur in the subject in quest ion:
•Withdrawal o f consent from the study
•Withdrawal o f consent fr om further treatm ent wi th invest igational product 
•Lost to follow -up
•AEor significant l aboratory abnormalit y that, in the opinion o f the invest igator and/or the 
sponsor, warrants discontinuation o f further dosing
•Pregnancy or a decisio n to become pregnant (see Section 5.6.3 )
•Subjects who require bio logic DMARD therapy  other than MEDI4920
•Hepati c funct ion abnormalit y defined as any  increase in ALT or AST to greater than 
3×ULN and concurrent increase in bilirubin to greater than 2 ×ULN rel ated to 
MEDI4920 :
•Anaphylaxis or a serious hypersensit ivityreact ion.
•Any life -threatening or seri ous infect ion or opportunist ic infection. Subjects with a 
diagnosis of serious and/or opportunistic infect ionsincluding but not limited to
reactivat ion of TB, hepat itis B, or hepatit is C will not receive any further invest igational 
product .
•Any confirmed or suspected serious or severe thromboembo lic event
•AEsof malignanc y
Subjec ts who are perm anent ly discont inued fro m receiving invest igational product will be 
followed for protocol -specified assessments including fo llow-up of  any AEs unless consent 
is wit hdrawn from further study  parti cipat ion (Sectio n4.1.5 ), or the subject i s lost to f ollow -
up.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
36of 98 Template 16.24.1.7 Replacement of Subjects
Only subjects who are randomized but do not receive invest igational product (MEDI4920 or 
placebo) may  be replaced to m aintain the sti pulated cohort sizes. This would include subjects 
who are randomized and then wit hdraw consent before receipt of invest igational product. 
4.1.8 Withdrawal of Informed Consent for Data and Biological Samples
Biological Samples Obtained for the Main St udy
Study  data are protected by  the use of an SID number, which is a number specific to the 
subject. The invest igator is in control of the information that is needed to connect a study 
sample to a subject. A subject’s consent to the use of data does not ha ve a specific expirat ion 
date, but the subject may wit hdraw consent at any  time by notifying the invest igator. If 
consent is withdrawn, any samples collected prior to that time may st ill be given to and used 
by the sponsor but no new data or samples will b e collected unless specifically  required to 
monitor safet y of the subject.
Samples Obtained for Genetic or Future Research
Samples obtained for genetic or future research will be labeled wit h a sample ident ificat ion 
number. If the subject withdraws consent for parti cipat ing in the genetic or future research, 
the sponsor will locate the subject’s sample and destroy  it. 
If the subject consents to have his/her samples used for future research, this addit ional 
research may not start immediately and may  start at any t ime during the storage period. The 
subject’s sample(s) will be stored by  the sponsor wit h similar samples from other subjects at 
a secure central laboratory . The subject’s samples will not be kept for more than 25 y ears 
after the end of the study  in which they  were collected. If the subject chooses not to allow 
his/her study  samples to be used for future research, the samples will be destroy ed by  the 
sponsor once they  are no l onger requi red for the main study .
If consent is wit hdrawn, the sponsor an d the investigator will ensure that these sample(s) are 
destroy ed unless the i dentification number has been removed and the subject can no longer 
be linked to any  sample(s). However, if the subject’s samples have already been used for 
research, the sponsor is not required to destroy  resul ts of this research. In this case only the 
remaining sample(s) will be destroy ed.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
37of 98 Template 16.24.2 Schedule of Study Procedures
4.2.1 Enro llment/Screening Period
Table 4.2.1 -1shows all procedures to be conducted at the screening visit. Assessments 
shoul d be perform ed in the order shown in the table.
Whenever vital signs, 12 -lead ECGs, and blood draws are scheduled for the same no minal 
time, the blood draws shoul d occur last. The timing of the first 2 assessments should be such 
that it allows the bl ood draw (eg, serum chemistry ) to occur at the proper nominal t ime.
Table 4.2.1 -1 Schedule of Screening Procedures  
Study Period Screening
Visit Number V1
Procedure / Study Day Day -42 to Day -1
Written informed consent X
IXRS assignment of SID number X
Medical history X
Verify  eligibility  criteria X
Safety assessments
Assessment of AEs/SAEs X
Assessment of concomitant medications X
Complete physical examination (includes weight) X
Height X
12-lead ECGaX
Vital signsbX
TB test cX
Blood collection for:
Serum chemistry X
Hematology X
Coagulation parameters :
Screening for deficiency of protein C, protein S, AT3, 
and APL antibodiesX
Baseline coagulation panel X
Autoantibody panel (RF, RF isotypes , ACPA, ANA, 
anti-Ro, anti -La[serum])X
Explo ratory  biomarkers (serum) X
RNA PAXgene ( whole blood) X
Acute -phase reactants (CRP, ESRd) X
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
38of 98 Template 16.2Table 4.2.1 -1 Schedule of Screening Procedures  
Study Period Screening
Visit Number V1
Procedure / Study Day Day -42 to Day -1
Virology: hepatitis A, B, C; HIV -1, HIV -2, CMV, EBV X
Serum β -hCG(females of childbearing potential only) X
Urine collection for:
Urinaly sis X
Rheumatoid assessments
TJC/SJC: 28 joints count X
VAS Patient’s Global Assessment of disease activity X
Physician’s Global Assessment X
AE = adverse event; ACPA = anti-cyclic c itrullinated peptide antibody; ANA = antinuclear antibod y; 
APL =antiphospholipid; AT = anti -thrombin; β-hCG = beta-human chorionic gonadotropin ;
CMV =cytomegalovirus ; CRP =C-reactive protein ; EBV = Epstein -Barr virus;ECG =electrocardiogram; 
ESR =erythrocy te sedimentation rate; HIV = human immunodeficiency virus; IXRS = interactive voice/web 
response system ; RF=rheumatoid factor ; RNA =ribonucleic acid; SAE = serious adverse event ; SID =subject 
identification; TB =tuberculosis; TJC = tender joint count; SJC=swollen joint count ;V= visit; VAS = visual 
analogue scale .
aThe screening ECG will be obtained in triplicate (all 3 within a 5 -minute time period, at least 1 minute 
apart).
bVital sign measurements include body temperature, blood pressure, heart [ pulse ]rate, and respiratory rate.
cTB screening will be performed according to the local medical standards .If the local stan dard requires a 
chest X -ray it must be from within the last 6 months prior to screening and source documents must be 
available. QuantiFERON®-TB Gold test at screening will be mandatory for all subjects and will constitute 
an exclusion criterion per se . 
dESR will be analyzed at the local laboratories.
4.2.2 Treatment Period
Table 4.2.2 -1shows all procedures to be conducted during the treatment period (Part A 
through Day  85[Week 12]).
Whenever vital signs, 12 -lead ECGs, and blood draws are scheduled for the same no minal 
time, blood draws should occur last. The timing of the first two assessments should be such 
that it allows the bl ood draw (eg, PK bl ood sam ple) to occur at the proper nominal time. All 
laboratory sample collect ions and assessments on dosing day mustbe perform edat predose , 
unless specified otherwise .
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
39of 98 Template 16.2Table 4.2.2 -1 Schedule of Treatment Period Study Procedures  
Study P eriod Treatment Period
Visit N umber V2 V3 V4 V5 V6 V7 V8 V9 V10
Procedure / Study DayDay 1
± 1 
DayDay 2
± 1
DaysDay 8± 
1 DayDay 15
± 1 DayDay 29
± 1 DayDay 43
± 1 DayDay 57
± 1 DayDay 71
± 1 DayDay 85
± 1 Day
Randomization
Verify  eligibility  criteria X
IXRS randomization call X
Safety assessments
Assessment of AEs/SAEs X X X X X X X X X
Assessment of concomitant medications X X X X X X X X X
Complete p hysical examination ( includes weight ) X
Abbreviated p hysical examinationaX X X X X X X
12-lead ECG X X
Vital sign sbX X X X X X X X X
Blood collection for:
Serum chemistry X X X X X X
Hematology X X X X X X
Coagulation panel X X X X X X
Autoantibody panel (RF, RF isotypes , ACPA, ANA, 
anti-Ro, anti -La [serum]) X X X X
Explo ratory  biomarkers (serum) X X X X X X
RNA PAXgene (whole blood) X X X X X
Acute -phase reactants (CRP, ESRc) X X X X X
CD4+ counts X X X X X X X
Flow cytometry (whole blood) X X X X
Vectra® DA (MBDA) (serum) X X X X X X
Total CD40L (plasma) X X X X X X
PK (plasma) X dX X X eX eX eX e
ADA (plasma) fX X X X
Anti-PAD4 antibody (serum) X X X X
Urine collection for:
Urinaly sis X X X X X X
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
40of 98 Template 16.2Table 4.2.2 -1 Schedule of Treatment Period Study Procedures  
Study P eriod Treatment Period
Visit N umber V2 V3 V4 V5 V6 V7 V8 V9 V10
Procedure / Study DayDay 1
± 1 
DayDay 2
± 1
DaysDay 8± 
1 DayDay 15
± 1 DayDay 29
± 1 DayDay 43
± 1 DayDay 57
± 1 DayDay 71
± 1 DayDay 85
± 1 Day
Urine β-hCG (women of childbearing potential only) X X X X X X X
Rheumatoid assessments
TJC/SJC : 28 joints count X X X X X
VAS Patient assessment of disease activity X X X X X
Physician’s global assessment X X X X X
Investigational product administration X X X X X X X
ADA = anti -drug antibody; AE = adverse event; ACPA = anti-cyclic c itrullinated peptide antibody; ANA = antinuclear antibod y; Anti -PAD4 =antibody 
against isoform 4 of peptidyl arginine deiminase; β-hCG = beta -human cho rionic go nadotropin; CRP = C-reactive protein; ECG =electrocardiogram; ESR = 
erythrocy te sedimentation rate; IXRS =interactive voice/web response system; MBDA = multi -biomarker disease activity; PK = pharmacokinetic; RF = 
rheumatoid factor; RNA = ribonucleic acid; SAE =serious adverse event ; CD40L = CD40 ligand; TJC = tender joint count; SJC=swollen joint count ; V = 
visit; VAS = visual analog uescale.
Note: An overnight stay prior to administration of investigational product on Day 1 is recommended but not mandatory. An over night stay  post -investigational 
product administration on Day 1 is ma ndato ry.
Note: All laboratory sample collections and assessmen ts on dosing day must be performed at predose , unless specified otherwise .
Note: RA assessments on dosing day should be performed at predose .
aAbbreviated physical examination includes cardiovasc ular, respiratory  and nervous system examinations.
bVital sign measurements include body temperature, blood pressure, heart [pulse] rate, and respiratory rate. On the first two dosing days (Day 1 and 
Day 15), vital signs will be measured within 30 minutes prior to the start of infusion, ever y 30 minutes (± 5 minutes) during the infusion, at the end of the 
infusion (+ 5 minutes), then at 1 hour, 2 hours and 4 hours after the end of infusion (± 10 minutes). On subsequent dosing days, vital signs will be 
measu red within 30 minutes prior to the start of infusion, every 30 minutes (± 5 minutes), and at the end of the infusion (+ 5 minutes). 
cESR will be analyzed at the local laboratories.
dBlood sample for PK on Day 1 collected post -dose only (at the end of infusion) .
eBlood samples for PK on Days 15, 29, 57 and 85 collected pre -and post -dose (at the end of infusion) .
fBlood samples for ADA collected at predose only.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
41of 98 Template 16.24.2.3 Follow -up Period
Table 4.2.3 -1shows all procedures to be conducted during the fo llow-up period. 
Assessments should be perfo rmed in the order shown in the table.
Whenever vital signs, 12 -lead ECGs, and blood draws are scheduled for the same no minal 
time, blood draws should occur last. The timing of the first two assessments should be such 
that it allows the bl ood draw ( eg,PK blood sample) to occur at the proper nominal time .
Table 4.2.3 -1 Schedule of Follow -up Procedures
Study P eriodFollow -up Period
FU1 FU2 FU3 FU4 FU5
Visit N umber V11 V12 V13 V14 V15
Procedure / Study DayDay
92± 3 
DaysDay
99± 3 
DaysDay
113± 3 
DaysDay
141± 3 
DaysDay 169
± 3 Days
/EDV
Safety assessments
Assessment of AEs/SAEs X X X X X
Assessment of concomitant medications X X X X X
Complete physical examination (includes 
weight)X
Abbreviated p hysical examinationaX X X X
12-lead ECG X
Vital sign sbX X X X X
Blood collection for:
Serum chemistry X X X X X
Hematology X X X X X
Coagulation panel X X X X X
Autoantibody panel (RF, RF isotypes, ACPA, 
ANA, anti -Ro, anti-La [serum])X
Explo ratory  biomarkers (serum) X X
RNA PAXgene (whole blood) X
Acute -phase reactants (CRP, ESRc) X X X
CD4+ counts X X X
Flow cytometry (whole blood) X X
Vectra DA (MBDA) (serum) X X
Total CD40L (plasma) X X
PK (plasma) X X X X X
ADA (plasma) X X
Urine collection for:
Urinaly sis X X X X
Urine β-hCG (women of childbearing potential 
only)X X X X
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
42of 98 Template 16.2Table 4.2.3 -1 Schedule of Follow -up Procedures
Study P eriodFollow -up Period
FU1 FU2 FU3 FU4 FU5
Visit N umber V11 V12 V13 V14 V15
Procedure / Study DayDay
92± 3 
DaysDay
99± 3 
DaysDay
113± 3 
DaysDay
141± 3 
DaysDay 169
± 3 Days
/EDV
Rheumatoid assessments
TJC/SJC: 28 joints count X X X
VAS Patient’s assessment of disease activity X X X
Physician’s global assessment X X X
AE = adverse event; ACPA = anti-cyclic c itrullinated peptide antibody; ANA = antinuclear antibod y;
β-hCG =beta-human cho rionic go nadotropin ; CRP = C-reactive protein ;ECG = electrocardiogram; EDV = 
Early  Discontinuation Visit; ESR =erythrocy te sedimentation rate; FU=follow -up; MBDA = multi -
biomarker disease activity ; PK =pharmacokinetic; RF = rheumatoid factor; RNA =ribonucleic acid; SAE = 
serious adverse event ; CD40L = CD40 ligand; TJC =tender joint count; SJC = swollen joint count; V = visit; 
VAS =visual analog uescale.aAbbreviated physical examination w ill include cardiovascular, respiratory and nervous system 
examinations.
bVital sign measurements include body temperature, blood pressure, heart [pulse] rate, and respiratory 
rate.
cESR will be analyzed at the local laboratories.
4.3 Description of Study Procedures
4.3.1 Medical History ,Physical Examination , Electrocardiogram , Weight, 
Height, and Vital Signs
4.3.1.1 Medical History
A complete m edical history  will be obtained at screening and will include past and current 
medical condit ions such as cardio vascular disorders, respiratory , gastrointestinal, renal, 
hepat ic, neurological, endocrine, lymphat ic, hematologic, immunologic, dermatological, 
psychiatri c, geni tourinary , drug and surgical history , and/or any  other di seases or di sorders.
4.3.1.2 Physical Examination, Height, and Weight
Com plete p hysical examinat ions(includin g wei ght) and abbreviated physical examinat ions 
will be performed by  a licensed hea lthcare provi der (i e, physician , physician’s assistant, or 
licensed nurse practit ioner). Complete physical examinat ionswill include assessment of 
weight, g eneral appearance, head, ears, eyes, nose, throat, neck, skin, as well as 
cardi ovascular, respi rator y, abdo minal, and nervous systems. Abbreviated physical 
examinat ions will include assessment of cardi ovascul ar, respi ratory , and nervous system s. 
Each clinically significant abnormal finding will be recorded in the electronic case report 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
43of 98 Template 16.2form (eCRF). Physical examinat ions will be performed at study  visits specified in 
Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1. Height will be measured at screening only.
4.3.1.3 Vital Signs
Vital signs ( body  temperature , BP, heart [pulse] rate, and respiratory rate) will be obtained at 
the visits specified in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1. 
On the first two dosing days (Day  1 and Day  15), vital signs will be measured wit hin 
30minutes prior to the start of infusion, every 30 minutes ( ± 5 minutes) during the infusio n,
at the end of the infusion (+ 5 minutes) , then at 1 hour, 2 hours and 4 hours after the end of 
infusio n (±10 minutes). On subsequent dosing days, vital signs will be measured within 
30minutes prior to the start of infusion, every 30 minutes (± 5 minutes), and at the end of the 
infus ion (+ 5 minutes). 
4.3.1.4 Electrocardiogram
Twelve -lead ECG recordings will be evaluated at screening and at the visits specified in 
Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1. 
At screening , the ECG will be performed in triplicate ( all 3 within a 5 -minute time period, at 
least 1 minute apart ) and the mean value of the triplicate measurement will be recorded as the 
baseline value. ECGs taken at all other tim es (ie, during the treatment period) will be single 
assessments.
All ECG recordings will be made with the subject in a supine posit ion having rested in this 
position for at l east 5 minutes before the start of the ECG.
All ECGs will be recorded at a speed of 25 mm /seconds wi th amplitude recording of 
10mm/mV. At least 3 full co mplexes m ust be recorded. A mult i-channel ECG m achine 
shoul d be used (equals 3 l eads recorded simultaneously) and there must be amplitude index 
calibrat ion for each lead.
Electronic s oftware will be used to assess the follo wing parameters: pulse rate, QRS, QT, and 
QTc time intervals. All ECGs must be reviewed by the principal invest igator or a qualified 
designee before the subject is permitted to leave the clinic. The occurrence of de -or re -
polarizat ion disorders, arrhy thmic disorders or other abnormalit ies will be assessed and 
obvious changes in ECG parameters from baseline will be assessed by the principal 
investigator for clinical significance. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
44of 98 Template 16.24.3.2 Clinical Laboratory Tests
A Laborator y Manual will be provided to the sites that specifies the procedures for 
collect ion, processing, storage, and shipment of samples, as well as laboratory  contact 
inform ation, specific to this clinical research study. The Laboratory Manual pertains to 
sample s that will be sent to a licensed central laboratory  (ie, sam ples f or clinical  laboratory  
safet y tests, PK, immunogenicit y, and bio marker analysis).
Clinical laboratory  safet y tests includ eserum  chemistry , hematol ogy, coagul ation, urinalysis, 
serum  pregna ncy tests , and other safety  tests (as outlined below) . Urine pregnancy  tests may  
be perform ed at the si te using a licensed test (dipstick). Clinically significant laboratory  
resul ts shoul d be repeated as soon as possible (preferably  within 24 to 48 hours).
The fo llowing clinical laboratory  tests will  be perform ed (see Table 4.2.1 -1, Table 4.2.2 -1, 
and Table 4.2.3 -1).
Serum Chemistry
•Calcium •ALP
•Chloride •TBL (if result is > 1.5 ULN, indirect and direct 
bilirubin will be measured)
•Magnesium •Creatinine
•Potassium •Blood urea nitrogen 
•Sodium •Glucose
•Bicarbonate •Albumin
•AST •Total protein
•ALT •Uric acid
•Cholesterol •Triglycerides
•IgA, IgG, IgE, IgM, total Ig
•Erythrocy te sedimentation rate (ESR)
Note for serum chemistry :Tests for AST, ALT, ALP, and TBL must be conducted concurren tly and assessed 
concurrently.
Hematology
•White blood cell (WBC) count with differential •Platelet count
•Red blood cell (RBC) count •Hemoglobin
•Hematocrit
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
45of 98 Template 16.2Coagulation
•International normalized ratio •D-dimer
•Prothrombin time •Fibrinogen
•Partial thromboplastin time •TAT
Urinalysis
•Color •Glucose
•Appearance •Ketones
•Specific gravity •Blood
•pH •Bilirubin
•Protein•Microscopy including WBC/high power field 
(HPF), RBC/HPF
Pregnancy Test (females of childbearing potential only)
•Urine β-hCG
•Serum β-hCG ( performed at screening only)
Other Safety Tests
•Hepatitis A antibody (IgM), HbsAg, HbsAb; HbcAb, hepatitis C antibody, hepatitis B virus DNA copy 
number (assessed at screening only)
•HIV-1 antibody , HIV -2antibody (assessed at screening only), sample for collection and retention for CMV 
and EBV (at screening only)  
•Protein S, Protein C, anti-thrombin 3, antiphospholipid antibodies (assessed at screening only)
•TB tes t (eg, QuantiFERON -TB Gold Test) as per local standard of care guidelines (assessed at screening 
only)
•Auto antibody panel : RF, RF isotypes (IgA, IgG, IgM), ACPA, anti-nuclear antibody ( ANA ), anti -Ro, 
anti-La
•Acute -phase reactants: C -reactive protein (C RP)and ESR
4.3.3 Pharmacokinetic Evaluation and Methods
Plasma sam ples to determine the concentration of MEDI4920 will be collected at the visits 
specified in Table 4.2.2 -1and Table 4.2.3 -1. MEDI4920 plasma concentrations will be 
measured by MedImmune using a validated immunoassay.
4.3.4 Immunogenicity Evaluation and Methods
Plasma sam ples w ill be collected for the assessment of ADA against MEDI4920 at the visits 
specified in Table 4.2.2 -1and Table 4.2.3 -1. Samples will be measured for the presence of 
ADA by  MedImmune using a validated immunoassay . Sample m ay be used for further 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
46of 98 Template 16.2characterizat ion of the ADA response, including possible assessment of neutralizing 
antibody .
4.3.5 Biomarker Evaluation and Methods
4.3.5.1 Flow Cytometry
Blood sam ples will be collected for the assessment of changes in the number, activat ion 
status and frequency o f major l eukocy te populati ons, incl uding B lymphocy tes, 
T lymphocy tes, and natural  killer ce lls using flow cy tometry according to the schedule of 
events as outlined in Table 4.2.2 -1and Table 4.2.3 -1.
A CD40L blockade is expected to reduce the frequency o f certain B -cell and 
plasmablast/pl asma cell popul ations and may indirectly also reduce the frequency o f T cells 
and other immune cell populat ions.
4.3.5.2 Autoantibody Panel
Serum will be collected to assess the presence of ACPA, RF, RF isoty pes, ANA, ant i-Ro, and 
anti-La according to the schedule of events as outlined in Table 4.2.1 -1, Table 4.2.2 -1, and 
Table 4.2.3 -1.
4.3.5.3 Exploratory Serum Biomarkers
Serum  will be collected to m easure changes in exploratory  biomarkers of disease activit y, 
autoantibodies associated with RA such as  
, according to the schedule of events as outlined in 
Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1.
Thes e biomarker m easurem ents will aid in determining what biological pathways are 
impacted by  MEDI4920 treatm ent. 
4.3.5.4 Total CD40L Levels
Plasma sam ples will be collected for the measurement of total CD40L levels (free and 
bound) as a m easure of target engagement by MedImmune using a qualified immunoassay 
method according to the schedule of events as outlined in Table 4.2.2 -1and Table 4.2.3 -1.
4.3.5.5 Blood Transcrip tome
Blood RNA will  be used to m easure the expressio n levels of genes associated with disease 
activit y, specific cell ty pes and signaling including the CD40L -CD40 pathway . The se 
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
47of 98 Template 16.2biomarker m easurements will aid in the determinatio n of what bio logical pathways are 
impacted by  MEDI4920 treatm ent. 
A blood sam ple will be collected using the PAXgene Blood RNA System for the collect ion, 
transport, and storage of blood and stabilizat ion of  intracellular RNA in a closed tube and 
subsequent i solation and purificat ion of intracellular RNA from who le blood for microarray  
analysis and quant itative PCR. RNA PAXgene blo od sam ples will  be collected according to 
the schedule o f events as outlin ed in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1.
4.3.5.6 MBDA Test
A co mmercially available and validated bio marker panel (Vectra DA) measures 
12biomarkers and co mbines them into a single score to assess the key mechanisms and 
pathways that drive RA disease act ivity. The bi omarker panel  includes adhesio n molecules, 
growth factors, cy tokines, m atrix metalloproteinases, skeletal proteins, hormones and acute 
phase proteins. The MBDA bio marker panel has been demo nstrated to be a sensit ive 
objective measure of clinical disease act ivity, with a strong correl ation to DAS28 CRP. 
Changes in MBDA score are also an object ive measure of changes in disease act ivity, 
showing a significant correlat ion to changes in DAS28 CRP. Serum samples will be collected 
for the Vectra DA (MBDA) bio marker panel according to the schedule of events as outlined 
in Table 4.2.2 -1and Table 4.2.3 -1.
4.3.6 Disease Evaluation and Methods
The RA assessments should be performed prior to the treatment infusio n if on a dosing day.
4.3.6.1 Tender and Swollen Joint Counts
The tender j oint count (TJC) and swollen jo int count (SJC) assess the fo llowing 28 j oints for 
tenderness and swelling: the 8 proximal interphalangeal jo ints of the fingers, the 
interphalangeal jo ints of the thumbs (n =2), the 10 metacarpophalangeal jo ints plus the 
wrists (n = 2), elbows (n = 2), shoulders (n = 2), and knees (n = 2) ( Prevoo et al, 1995 ).
The TJC and SJC will be assessed by  a qualified, independent, blinded Jo int Counts 
Assessor. This person will be responsible for complet ing the TJC and SJC wi thout access to 
any other study -related outcomes. The TJC and SJC will be performed according to the 
schedule of events as outlined in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
48of 98 Template 16.24.3.6.2 Patient’s Global Assessment of Disease A ctivity
The Pa tient’s Gl obal Assessment (PGA) of di sease activit y is a measure of the patient’s 
general healt h on a 100 mm visual analogue scale (VAS) from 0 mm = best to 
100mm=worst and will be performed according to the schedule of events as outlined in 
Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1.
4.3.6.3 Physician Global Assessment of Disease A ctivity
The Physician’s Global Assessment (MDGA) of disease act ivity is a 100 mm VAS that asks 
the invest igator to rate their subject’s current diseas e activit y on a scale of 0 mm ( none) to 
100mm (extremely act ive). The MDGA will be performed according to the schedule of 
events as outlined in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1.
4.3.6.4 Acute -phase Reactants
Blood sam ples f or acute -phase reactants, CRP and ESR, will be collected according to the 
schedule of events as outlined in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1. Both CRP 
and ESR are strong correlates of disease act ivity in RA. 
Disease Activity Score in 28 Joints Using C -reactive Protein
The DAS28 CRP considers 28 of the 68 TJC and 28 of the 66 SJC , general healt h (GH; PGA 
[0-100 mm VAS] ), plus levels o f an acute -phase reactant ( CRP [mg/L] ). CRP l evels are m ore 
sensit ive to short -term changes in disease activit yand more specific to inflammatory  
condi tions, whereas ESR i s less specific and can be influenced by a number of unrelated 
factors, such as age, gender, red blood cell count ,or plasma proteins .
DAS28 CRP values will be calculated as follows ( Wells etal, 2009 ):
DAS28 CRP = 0.56 × square root (sqrt) (TJC28) + 0.28 × sqrt(SJC28) + 0.014 × GH +
0.36 × ln(CRP+1) + 0.96
Clinical Disease Activity Index
The CDAI i s a com posite index (wit hout acute -phase reactant) for assessing d isease act ivity 
and is defined as the sum of the TJC (using 28 jo ints), the SJC (using 28 joints), the PGA 
(0-100 mm VAS), and the MDGA (0 -100 mm VAS). The CDAI has a range fro m 0mmto 
76mm.The greatest advantage associated with CDAI is its potential to be emplo yed in 
evaluat ion of pat ients with RA consistent ly with close frequency  and independently o f any 
calculat ing device ;therefore, i t can essent ially be used every where and any time for disease 
activit y assessment in RA patients .
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
49of 98 Template 16.24.3.7 Estimate of Volume of Blood to Be Collected
The est imated volume of blood to be collected from each subject at each visit (and across all 
visits) fro m screening through Day  169/Early Discontinuat ion Visit (EDV) is presented in 
Table 4.3.7 -1. If repeats of any blood tests are required, the volume of blood collection will 
increase accordingly.
Table 4.3.7 -1 Estimate of Blood Volume to Be Collected
Visit Day Estimated Blood Volume (mL)
Day -42to Day -1 (Screening) 65.9
Day 1 59.5
Day 2 9
Day 8 35.5
Day 15 48.5
Day 29 58
Day 43 10
Day 57 59
Day 71 10
Day 85 59
Day 92 18.8
Day 99 21.5
Day 113 46.5
Day 141 18.8
Day 169/EDV 52
Total 572
EDV = Early Discontinuation Visit.
4.4 Study Suspension or Termination
The sponsor reserves the right to temporarily  suspend or permanently terminate thi s study  at 
any time. The reasons for temporarily suspending or permanent ly terminat ing the study may 
include but are not limit ed to the fo llowing: 
1.The incidence or severit y of AEs in this or other studies indicates a potential health 
hazard to subjects .
2.Subject enro llment is unsat isfactory
3.Non-compliance that might significant ly jeopardize the validit y or integri ty of the study
4.Sponsor decisio n to terminate development of the investigational product for this 
indicat ion
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
50of 98 Template 16.2If MedImmune determines that temporary  suspension or permanent terminat ion of the study  
is required, MedImmune will discuss the reasons for taking such act ion with all parti cipat ing 
investigators (or head of the medical inst itution, where applicable). When feasible, 
MedImmune will provide advance notice to all participat ing invest igators (or head of the 
medical inst itution, where applicable) of the impending act ion.
If the study  is suspended or terminated for safet y reasons, MedImmune will prompt ly inform  
all invest igators, heads of the medical inst itutions (where applicable), and/or inst itutions 
conducting the study . MedImmune will also promptly  inform the rel evant regul atory  
authori ties of the suspensio n/terminat ion alo ng with the reasons for such act ion. Where 
requi red by applicable regulat ions, the investigator or head of t he medical inst itution m ust 
inform  the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)prom ptly 
and provide the reason(s) for the suspensio n/terminat ion. If the study  is suspended for safet y 
reasons and it is deemed appropriate by  the s ponsor to resum e the study , approval  from the 
relevant regul atory  authori ties (and IRBs/IECs when applicable) will be obtained prior to 
resuming the study .
4.5 Investigational Products
4.5.1 Identity of Investigational Product s
MedImmune will provide the invest igato r(s) with investigational product ( Table 4.5.1 -1) 
using designated distribut ion centers. 
Table 4.5.1 -1 Identification of Investigational Products 
Investigational Product ManufacturerConcentration and Formulation as 
Supplied
MEDI 4920 (250 mg/vial) MedImmune, LLC 20 mL lyophilized vial with a nominal 250 mg
of MEDI4920 at a post-reconstitution 
concentration of 
50 mg/mL, containing 10 mM sodium 
monobasic/dibasic phosphate, 250 mM 
sucro se and 0.02% (w/v) polysorbate 80,
pH 7.4
Placebo Provided by the site 0.9% saline for injection
(w/v) = (weight/volume)
MEDI4920 will be supplied by MedImmune to the si te in containers wit h ident ical 
appearances in coded, open -label kits. Each ki t has a unique number that is printed on all 
labels wit hin the kit (ie, the outer carton label and the label o f each container within the 
carton). Each carton is labeled with a unique number range that corresponds to the labeled 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
51of 98 Template 16.2number series of the containers within the carton .Placebo will  be prefilled IV saline bags 
sourced by  each si te.
4.5.1.1 Investigational Product Handling
The invest igational product manager will select the MEDI4920 vials assigned by the IXRS to 
prepare the subject’s dose. For subjects assigned to placebo, the si tes shoul d use prefilled IV 
saline bags only.
Do not rem ove MEDI4920 fro m 2°C to 8°C (36°F to 46°F) storage until all procedures for 
subject dosing have been co mpleted. When preparing a dose for administration, immediately 
remove the vial s from the carton and replace the carton in 2°C to 8°C (36°F to 46°F) storage.
The invest igational product manager/unblinded study personnel must ensure that only the 
unblinded team members have access to the areas of the pharmacy where the invest igational
product is being prepared.
4.5.1.2 Investigational Product Inspection
Each vial selected for dose preparation should be inspected. MEDI4920 is supplied as a 
sterile ly ophilized drug product with post -reconstitution concentration of 50 mg/mL.
If there are any defects noted wi th the invest igational product, the invest igator and site 
monitor shoul d be notified immediately. Refer to the Product Complaint sec tion for further 
instructi ons (Secti on 4.5.1.9 ).
4.5.1.3 Dose Preparation Steps
No incompat ibilities between MEDI4920 and plastics passing co mpat ibility tests (i e, 
polyethylene bags; po lyethylene and polyvinyl chloride infusio n lines; polypropylene and 
polycarbonate sy ringes for IV infusio n using IV infusio n pum p) have been observed. 
MEDI4920 does not contain preservatives and any unused portions must be discarded. 
Preparati on of  investigational product and IV bags isto be perform ed asept ically. Total  
in-use storage time fro m reconstitution of  investigational product/needle puncture of the 
investigat ional product vial to start of administration should not exceed 4 hours at room 
temperature or 24 hours at 2 °C to 8°C (36 °F to 46°F). If storage time exceeds these limits, a 
new dose m ust be prepared fro m new vials.
Each vial o f investigational product must be reconstituted with 5.0 mL o f sterile water for 
inject ion to achieve 5.5 mL (5 mL no minal) o f 50 mg/mL MEDI4920.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
52of 98 Template 16.24.5.1.4 Reconstitution Procedure
Slowly  add 5.0 m L of sterile water for inj ection by tilt ing the vial to one side such that the 
liquid stream is directed along the vial wall and not direct ly onto the lyophilized cake. Gent ly 
swirl the sol ution and repeat this procedure until all so lids are disso lved. DO NOT SHAKE 
OR VIGOROUSLY AG ITATE THE VIAL. Visually  inspect the sol ution to ensure that the 
entire content of the ly ophilized cake i s completely reconstituted. The reconstituted solut ion 
shoul d appear clear to opal escent. A thin layer of bubbles on the surface o f the liquid is 
norm al.
4.5.1.5 Preparation of Intravenous Dose
For Subjects Randomized to the MEDI4920 Group :
Preparati on of  MEDI4920 doses for IV infusio n with an IV infusio n pump :
The dose preparation steps are as fo llows:
1.For each of the IV doses (ie, 75, 500, 1000, and 1500 mg), the volume o f 0.9% saline 
(weight/vol ume [w/v]) equivalent to volume of MEDI4920 is removed first and then the 
requi red vo lume of MEDI4920 will be added to a prefilled IV bag ( Table 4.5.1.5 -1). 
Syringes used to prepare the IV bag must be polycarbonate or polypropylene.
2.A vial should be used only one t ime to prepare a single dose. The required vo lume o f 
MEDI4920 ( Table 4.5.1.5 -1) will be obtained by pooling the contents of as many 
MEDI4920 vials as necessary  (ie,1vialfor the 75mg dose, 2vials for the 500 mg dose, 
4vials for the 1000 mg dose, and 6 vials for the 1500 mg dose) with an appropriately
sized sy ringe. For ease of preparation, a 1.5 -inch 20 -gauge wi thdrawal  needle shoul d be 
used. Use a new needle for withdrawing invest igatio nal product from each vial.
3.Gent ly mix the contents of the IV bag. The admixt ureshoul d then be inspected to ensure 
the solution is clear.
Table 4.5.1.5 -1 MEDI4920 Dose Preparation for IV Infusion with an IV 
Infusion Pump
Dose (mg)Prefilled IV Bag Size 
(mL)Volume of Saline Removed 
from IV Bag (mL)MEDI4920 Dose Volume 
Added to IV Bag (mL)
75 50 1.5 1.5
500 100 10 10
1000 250 20 20
1500 250 30 30
IV = intravenous; FTIH = first time in human; SAD = single ascending dose.
Note: The maximum concentration of reconstituted investigational product solution will not exceed that used 
in the FTIH SAD study.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
53of 98 Template 16.2For Subjects Randomized to thePlacebo Group:
Preparati on of  placebo for IV infusio n with an IV infusi on pum p:
For each of the doses, the prefilled IV saline bag size to be used i s listed in Table 4.5.1.5 -2. 
No addi tional IV bag preparat ion is required.
Table 4.5.1.5 -2 Placebo Dose Preparation for IV Infusion with an IV 
Infusion Pump
Dose (mg) Prefilled IV Bag Size (mL)
75 50
500 100
1000 250
1500 250
IV = intravenous
During preparation of the invest igational product infusio n, the capacit y of the tubing shoul d 
be calculated in order to adjust the vo lume of investigat ional product solut ion needed to 
prime the IV tubing. This step is necessary  because the sam e volume o f saline will be needed 
at com pletion of the infusio n to flush the IV tubing in order to deliver the complete v olume 
of investigational product solution. Because the IV tubing contains invest igational product 
solution, the flush must be infused using the same infusio n rate as that used for the 
investigat ional product solut ion in the infusion bag.
For example, if th e IV tubing capacit y is 15 mL, the IV tubing should be primed wit h 15 m L 
of investigational product solution fro m the infusio n bag before init iating the infusio n. Once 
the infusion bag is empty , the IV tubing shoul d be flushed wit h at l east 15 mL of 0.9% s aline 
(w/v) via the infusio n pum p at the same rate as dosing.
The start time of the infusio n will be the time when infusio n of the invest igational product 
solution from the infusio n bag (with IV tubing primed with invest igational product solut ion) 
is start ed. The stop time of the infusio n will be the time when the IV tubing has been flushed 
with a vo lume of 0.9% normal saline equivalent to IV tubing capacit y (eg, 15 mL for the 
example above) to administer the residual invest igational product sol ution.
4.5.1.6 Intravenous Administration
All Cohorts (1 -4) will be administered invest igational product via IV infusion using an IV 
infusio n pum p.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
54of 98 Template 16.2Each subject in each cohort must receive the ent ire vol ume of  investigational product 
solution in the IV bag. Table 4.5.1.6 -1provides the duration of infusio n and flow rate by  
dose l evel. Investi gational product m ust be infused through a low -protein binding 0.2 -or 
0.22-μm in-line filter using an IV infusio n pum p.
Table 4.5.1.6 -1 Intravenous Administration of Investigational Product
Cohort Dose (mg)Total Volume in 
IV Bag (mL)Minimum 
Administration Time 
(min)Flow Rate at 
Minimum Time 
(mL/min)
1 75 50 (IV bag) 30 1.7mL/min
2 500 100(IV bag) 60 1.7mL/min
3 1500 250 (IV bag) 90 2.8mL/min
4 1000 250 (IV bag) 90 2.8mL/min 
IV = intravenous; min = minute; TBD = to be determined
4.5.1.7 Treatment A dministration
The first day of dosing is considered Day 1.
Each dose of invest igational product should be administered using the following guidelines:
•Female subjects must have a negat ive urine pregnancy test prior to receiving MEDI4920 
or placebo.
•A physician must be present at the site or immediately available t o respond to 
emergencies during administration of invest igational product. Fully  functional 
resuscitat ion facilit ies should be available.
•Invest igational product will be administered as a single IV infusio n as described in 
Table 4.5.1.6 -1. 
4.5.1.8 Monitoring of Dose A dministration
Vital signs (BP, heart [pulse] rate, respiratory  rate, and body  temperature) will be obtained as 
outlined in Table 4.2.1 -1, Table 4.2.2 -1, and Table 4.2.3 -1). In addit ion, if signs and 
symptoms indicat ive of an infusio n react ion occur, the infusio n will be stopped or slowed 
according to the judgment of the invest igator.
As wi th any biologic prod uct, allergic react ions to dose administration are possible. 
Therefore, appropriate drugs and medical equipment to treat acute anaphylactic reactions 
must be immediately available, and study  personnel must be trained to recognize and treat 
anaphylaxis.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
55of 98 Template 16.24.5.1.9 Reporting Product Complaints
Any defects with the invest igational product must be reported immediately to the 
MedImmune Product Complaint Department by the site with further notificat ion to the site 
monitor. All defects will be co mmunicated to MedImmune and i nvest igated further with the 
Product Complaint Department. During the invest igation of the product complaint, all 
investigat ional product must be stored at labeled condit ions unless otherwise instructed.
MedImmune contact informat ion for reporting product complaints:
Email:
Phone:
Fax:
Mail: MedImmune
Attn: Product Complaint Department
One MedImmune Way,
Gaithersburg, MD USA 20878
4.5.2 Additional Study Medications
4.5.2.1 Background Medications for RA  
All permitted background medicat ions from  initiation of screening through to the end of the 
study  must be recorded i n the source records and include the specific indicat ion for use as 
well as the dose, start and s top dates, frequency , and route of administrati on. 
MTXand Other cDMARDs
All subjects (except patients with intolerance to MTX or having been switched to another 
cDMARD after MTX failure) must be on MTX (7.5 to 25 mg/week) administered the same 
route (oral or injectable ), for at l east 12 weeks and at a stable dose for at least 6 weeks prior 
to screening . Subjects m ustcontinue with the same dose and route of administration for 
MTX during the 12- week treatm ent peri od (Days 1 to 85). Any dose changes in background 
MTX shoul d be di scussed and agreed with the medical mo nitor. Changes in MTX dose are 
permitted for safet y/tolerabili ty reasons ( which must be clearly  docum ented ) or, after 
Week 12 for control of disease act ivity. 
PPD
PPD
PPD
PPD
PPD
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
56of 98 Template 16.2To minimize MTX toxicit y,it isrecommended that subjects receive 5.0 mg/week fo lic acid 
during the study  as a single or divided dose. 
It is recommended that MTX is withheld if liver funct ion test s(LFT s), particularly ALT or
AST enzymes , are increased to > 3 × ULN and MTX dose should be reduced by 
2.5mg/week if LFT enzymes are increased between 2 and 3 ×ULN. After normalizat ion of 
the LFT, MTX can be reinit iated and/or titrated up to the dose used prior to modulat ion. In 
case of newly occurred bl ood cy topeni as (WBC < 3 ×109/L, neutr ophil count < 2×109/L, 
platelet count < 150 ×109/L) MTX should be withheld until blood cell counts recover. 
Protocol -permitted a lternat ive cDMARDs ( for subjects with docum ented MTX intol erance or 
if subject shave been treated with this DMARD after a pr evious MTX failure) are 
leflunomide, sulfasalazine, hydroxychloroquine , azathi oprine, D -penicillamine ,and 
cyclosporine . These m ust be given at the doses specified by the local RA treatm ent
guidelines and the local Summary of Product Characterist ics. Subject sshoul d be treated wi th 
the alternative cDMARD for at least 12 weeks and at a stable dose for at least 6 weeks prior 
to screening . Subjects m ust continue with the same dose and route of administration during 
the 12-week treatment period (Day s 1 to 85). Changes in dose are permitted for 
safet y/tolerabili ty reasons ( which must be clearly documented ) or, after Week 12 for control 
of disease activit y.
Corticosteroids 
Corti costeroi ds shoul d be maintained at a stable oral dose (< 10 m g equivalent 
prednisone/day) for the duration of the study  through to the end of the 12 -week treatment 
period unl ess changes are needed for safet y reasons. Any  change in background oral 
corticosteroi ds, or addi tion of injectable corticosteroids, is prohibited from 4 weeks prior to 
Day 1 up to Week 12(Day  85), unl ess used for the treatment of a non -RA AE. It is strongly  
recommended to avoid changes in corticosteroids dosage within 4 weeks prior to the 
Week 12 (Day  85) visit to avoid confounding the evaluat ion of efficacy . After Week 12, a 
change in oral corticosteroid dose and/or addit ion of injectable corticosteroids for control of 
disease act ivityis permitted . A maximum of 2 intra -articular inject ions of corti costeroids 
(upto 40 mg of triamcino lone or equivalent) can be allowed as required to control 
severe/refractory  mono/oligoarthri tis during the treatment period (no more than 4 jo ints 
allowed to be treated). Treated joint(s) will need to be excluded from the j oint counts un til 
12weeks post -inject ion. Intra -articular steroid injections are not allowed withi n 4 weeks 
prior to the Day 85(Week 12 ) visit to avoid confounding the evaluat ion of efficacy . Inhaled 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
57of 98 Template 16.2or topi cal corti costeroi ds given for asthma, COPD ,or dermatological condit ions are allowed 
provi ded doses are stable between screening and Day  85 visit.
Analgesics/NSAIDs
Analgesics and NSAIDs given primarily  for RA signs and symptom sshoul d be m aintained at 
a stabl e dose for the duration of the study  through to the end of the 12-week treatm ent peri od 
(Day  85) unless changes are needed for safet y/tolerabili ty reasons or inadequate response 
after the Week 12 visit. Subjects should refra in from taking the usual morning dose of 
analgesics on visit days unt il after all clinical assessments have been completed.
4.5.3 Labeling
Labels for the investigational product will be prepared in accordance wit h Good 
Manufacturing Practice and local regula tory guidelines. Label text will be translated into 
local languages, as required.
4.5.4 Storage
Invest igational product is to be stored at 2 to 8°C (36to 46°F).
4.5.5 Treatment Compliance
Invest igational product is administered by study  site personnel , who will monitor 
compliance.
4.5.6 Accountability
The invest igator’s or site’s designated unblinded investigational product manager is required 
to maintain accurate invest igational product accountabilit y records. Upon com pletion of the 
study , copies of invest igational pr oduct accountabilit y records will  be returned to 
MedImmune. All unused invest igational product will be returned to a MedImmune -
authori zed depot or disposed of upon authorizat ion by MedImmune.
4.6 Treatment Assignment and Blinding
4.6.1 Methods for Assigning Treatmen t Groups
An IXRS will be used for randomizat ion to a treatment group and assignment of 
investigat ional product kit numbers if assigned to an act ive treatment arm. A subject i s 
considered rando mized into the study  when the investigator notifies the I XRS that the subject 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
58of 98 Template 16.2meets eligibilit y criteria and the I XRS provides the assignment of treatm ent group and 
allocates act ive treatment if assigned to the active treatment arm .
Subjects will be rando mized ina 4:1 rati o (Cohort 1), in a 5:2 ratio (Cohort 2), in a 3:1 rati o 
(Cohort 3), and in a 5:2 ratio (Cohort 4) to receive either MEDI4920 or placebo respectively 
as described in Table 3.1.2 -1. 
Invest igational product (MEDI 4920 or placebo) must be administered the same day  the 
investigat ional product is assigned. If there is a delay  in the administration o f investigational 
product such that it will not be administered within the specified timeframe, the study  
monitor must be n otified immediately.
4.6.2 Methods for Ensuring Blinding
This is a double -blind study  in which MEDI 4920 and the saline placebo are not ident ical in 
appearance. As such, neither the subject/legal representative nor any o f the invest igator or 
sponsor staff who are invo lved in the treatment or clinical evaluat ion of the subjects will be 
aware of the treatment received ( ICH E9) (see Sectio n4.6.4 for unblinding related to interim 
analysis). For m aintaining the blinding of the principal invest igator, site staff, sponsor, 
Contract Research Organization (CRO) or sta ff, a local unblinded pharmacy staff member 
will be no minated by each site and will have the responsibilit y of allocat ing, dispensing and 
preparing the invest igational product in order to maintain the study blind. In addit ion, a 
separate unblinded mo nitor will be used for the oversight of invest igational product 
management. If treatm ent all ocati on for a subj ect becom es known to the invest igator or other 
study  staff invo lved in the management of study  subjects, the sponsor must be notified 
immediately .
4.6.3 Metho ds for Unblinding
4.6.3.1 Unblinding in the Event of a Medical Emergency
In the event of a medical emergency, the invest igator may unblind an individual subject’s 
investigat ional product allocat ion. Instructi ons for unblinding an individual subject’s 
investigat ional product allocat ion are contained in the I XRS manual. In general, unblinding 
shoul d only  occur if management of the medical emergency would be different based on the 
subject having received invest igational product. In the majorit y of cases, the m anagemen t of 
a medical emergency  woul d be the same whether or not invest igational product was received 
by the subject. If this was the case, the invest igational product allocat ion shoul d not be 
unblinded. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
59of 98 Template 16.24.6.4 Unblinding for Interim Analysis Purposes 
The primary  anal ysis will be performed when all subjects in Cohort 3 have completed the 
Day 85 assessments or have been withdrawn from the study . The primary  analysis will 
include all assessments on the subjects prior to the data cut -off for the primary  analysis.
MedImmun e personnel will be unblinded to the subject treatment assignment s from 
Cohorts 1to 3 at the primary analysis (Day 85). The data fro m the primary  analysis will not 
be co mmunicated to personnel at the CRO or investi gational sites or to enrolled subjects, 
until all subjects in Cohorts 1 to 3 have co mpleted the study and database lock has been 
achieved.
MedImmune personnel will be unblinded for Cohort 4 , and the data will be analyz edwhen 
all subjects in Cohort 4 have completed the Day  85 assessments or have been withdrawn 
from the study .Study  subjects and personnel at the CRO or invest igational sites will remain 
blinded to Cohort 4 data until all subjects in Cohort 4 have co mpleted the study and database 
lock has been achieved .
The final analysis on the subjects will be performed when all subjects have completed the 
safet y follow-up. 
4.7 Restrictions During the Study and Concomitant Treatment(s)
The i nvest igator must be informed as soon as possible about any medicat ion taken from th e 
time of screening until the end o f the clinical phase of the study  (final study  visit). Any 
concomitant medicat ion(s), including over-the-counter products (and any  herbal 
supplements) , taken during the study  will be recorded in the eCRF.
4.7.1 Permitted Concom itant Medications
Invest igators may prescribe concomitant medicat ions or treatments deemed necessary to 
provide adequate supportive care except for those medicat ions identified as “excluded” as 
listed in Section 4.7.2 . Specifically, subjects should receive full supportive care during the 
study , including transfusio ns of blood and blood products, and treatment with ant ibiotics, 
anti-emet ics, ant i-diarrheals, and anal gesics, and other care as deemed appropriate, and in 
accordance with their inst itutional guidelines.
4.7.2 Prohibited Concomitant Medications
Subjects m ust refrain from  alcoho l consumpt ion for 48 hours prior to all visits.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
60of 98 Template 16.2Subjects m ust refrain from  strenuous ex ercise for approximately  48 hours before each study  
day where safet y samples will be taken, and Day  169/EDV. Physical therapy  including
cold/hot applications, electrical st imulat ion, and hydrotherap y,applied specifically for RA, is 
not permitted between D ays 1 and 85. 
The introduction of the fo llowing medicat ions is not permitted fro m initiation of screening 
through to the end of the study . The sponsor m ust be notified if any  of the f ollowing 
medicat ions are given to a subject during the study (with the e xcepti on of  stable doses of 
DMARDs permitted prior to screening/rando mizatio n as applicable) : 
1. Invest igational drug therapy  other than MEDI4920
2. Biologic DMARD therapi es (such as ant i-TNF, recombinant IL -1 receptor antagonist, 
anti-IL-6, CTLA -4 Ig, B -cell depleting therapies, etc) or JAK inhibitors. 
3. Mycopheno late mofetil, cyclophosphamide, and other alkylat ing agents 
4. Live (attenuated) vaccine. Immunization wit h any live or live attenuated vaccine (ie, 
measles, mumps, rubella and polio vaccine , Bacillus Calmette -Guerin, ty phoid, 
yellow fever, cold adapted live influenza strain vaccine, or any  other vaccines not y et 
licensed but belo nging to this category ) is specifically  excluded during the treatment 
period(ACIP, 2011 ). 
5. Immunoabsorpti on col umns, total  lymphatic i rradiati on, pl asmapheresis and IV 
immunogl obulin therapy  
After Day  85, the dose of background cDMARDs and corticosteroids may  be adjusted or a 
new addit ional cDMARD may be added to an exis ting one (except for combining MTX and 
leflunomide) if it is clinically indicated to improve disease management. 
Subjects m ust be instructed not to take any  medicati ons or over -the-counter products 
(including herbal supplements), without first consult ing with the investi gator.
4.8 Statistical Evaluation
4.8.1 General Considerations
Tabular summaries will be presented by treatment group. Categorical data will be 
summarized by  the number and percentage of subjects in each category . Continuous 
variables will be summari zed by  descriptive statistics. Addit ional details o f statist ical 
analyses will be described in the statistical  analysis plan.
The intent -to-treat (ITT) populat ion is defined as all subjects who are randomized and 
receive any amount of investigational produ ct. Subjects will be analyzed by the rando mized 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
61of 98 Template 16.2treatm ent group. All efficacy and bio marker analyses will be performed on the ITT 
popul ation unless otherwise specified.
The as -treated popul ation is defined as all subjects who are randomized and treated wit h 
investigat ional product. Subjects will be analyzed by the treatment received. All safety 
analyses will be performed on the As-Treated populat ion unless otherwise specified.
4.8.2 Sample Size and Power Calculations
No formal sample size calculat ions are present ed for the evaluat ion of the primary  object ive 
of safet y and tol erabilit y of MEDI4920. The sample size calculat ions are based on the 
exploratory  endpoint
. 
The sample size calculat ionfor the change fro m baseline in DAS28 CRP at Week 12 is based 
on combining the data from the cohorts and performing a dose response analysis. Based on 
the assumption  
 the sample sizes of 14, 
8, 10 , 10and 12 subjects for the placebo, 75, 500 , 1000 and 1500 mg dose groups, 
respectively , will provi de approximately  92% power for detecting a statist ically significant 
dose respo nse, using a significance level o f 0.10.
The power for dose response has been calculated using a mult iple co mpar ison procedure with 
modeling techniques (MCP -Mod; Bretz et al , 2005 ), with three candidate models for the dose 
response (linear, maximum effect attributable to the drug [E max], and a Hill -Emaxmodel). An 
overall significance level o f 0.10 will be used to test for dose response.
4.8.3 Exploratory Efficacy Analyses
4.8.3.1
CCI
CCI
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
62of 98 Template 16.24.8.3.2
4.8.3.3
4.8.4 Safety
4.8.4.1 Analysis of Adverse Events
AEswill be coded using the Medical Dict ionary for Regul atory  Activities (MedDRA) by 
system  organ cl ass (SOC) and preferred term (PT). Specific AEs will be counted once for 
each subject for calculat ing rates, but will be presented in total in subject list ings. In addi tion, 
if the same AE occurs mult iple times wit hin a particular subject, the highest severit y and 
level of causalit y will be reported. If any associat ions of interest between AEs and baseline 
characterist ics are observed, addit ional stratified resu lts may be presented. All TEA Eswill be 
summarized overall and by  MedDRA SOC and PT, and by severit y and relati onship to 
investigat ional product. In addit ion, summaries of deaths, SAEs and treatment 
discontinuat ions due to AEs will be provided.
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
63of 98 Template 16.2TEAEs , treatment-emergent SAEs ( TESAEs )and AESIs with onset after the start of infusio n 
(Day  1) to Day  169/EDVinclusive will be summarized by dose. The placebo subjects fro m 
each cohort will be combined for the summaries.
Other safet y param eters, incl uding laborato ry assessments and vital signs, will be 
summarized by  dose.
4.8.4.2 Analysis of Clinical Laboratory Parameters
Laboratory  parameters will be assessed at baseline as well as throughout the study . 
Frequencies of abnormal laboratory  measurements will be presented for each laboratory  
param eter. Al so, laboratory  param eters will  be assessed by  presenting tabl es containing 
inform ation related to l aboratory  shift s from baseline relative to the normal range, as well as 
descript ively over time.
4.8.4.3 Other Safety and Tolerability Endpoints
Other safet y param eters, incl uding vi tal signs and ECGs, will be summarized by dose and 
time point. 
4.8.5 Analysis of Immunogenicity/Pharmacokinetics
The number and percentage of subjects who develop detectable ADA will be summarized by 
dose. The impa ct of ADA on PK and the associat ion with AEs and SAEs will be assessed. 
Plasma MEDI4920 concentration data at each time point will be tabulated by  dose cohort 
together with descript ive statist ics. Individual and mean plasma concentration -time profiles 
of MEDI4920 by  dose cohort will be generated. Non -compartmental  PK data analysis will be 
perform ed and descript ive statist ics for PK param eters will be provided.
4.8.6 Interim Analysis
The primary  analysis will be performed when all subjects in Cohort 3 have complet ed the 
Day 85 assessments or have been withdrawn from the study . The primary  analysis will 
include all assessments on the subjects prior to the data cut -off for the primary  analysis.
MedImmune personnel will be unblinded to the subject treatment assignment s from 
Cohorts 1 to 3 at the primary analysis (Day 85). The data fro m the primary  analysis will not 
be co mmunicated to personnel at the CR O or investi gational sites or to enrolled subjects, 
until all subjects in Cohorts 1 to 3 have co mpleted the study and database lock has been 
achieved . 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
64of 98 Template 16.2An addit ional interim analysis will be performed when all subjects in the C ohort 4 have 
completed the Day  85 assessments or have been wit hdrawn from the study .MedImmune
personnel will be unblinded to the subject treatm entassignment sfrom Cohort 4 for this 
interim analysis . Study  subjects and personnel at the CRO or investi gational siteswill remain 
blinded to Cohort 4 data until all subjects in Cohort 4 have co mpleted the study and database 
lock has been achieved .
The final analysis on the subjects will be performed when all subjects have completed the 
safet y follow-up. 
5ASSESSMENT OF SAFETY
5.1 Definition of Adverse Events
The ICH Guideline for GCP E6(R1) defines an AE as:
Any untoward medical occurrence in a patient or clinical invest igation subject 
administered a pharmaceutical product and which does not necessarily  have a causal  
relationship with this treatment. An AE can therefore be any unfavorable and unintended 
sign (incl uding an abnorm al laboratory  finding), sy mptom , or di sease tem porally 
associ ated wi th the use of a m edicinal product, whether or not considered related to the 
medicinal product.
An AE includes but is not limited to any  clinically  significant worsening of a subject’s pre -
exist ing condit ion. An abn ormal laboratory  finding (including ECG finding) that requires 
medical interventi on by  the invest igator, or a finding judged by the investigator as medically 
significant shoul d be reported as an AE. If clinical sequelae are associated with a laboratory  
abnormality, the di agnosis or m edical condit ion shoul d be reported (eg, renal failure, 
hematuri a) not the l aboratory  abnorm ality (eg, el evated creatinine, urine red bl ood cell
increased) . Abnormal laboratory  values that are not, in the invest igator's opinio n,medically 
significant and do not require intervent ion shoul d not be reported as AEs.
AEsmay be treatm ent em ergent (i e, occurring after init ial receipt of invest igational product) 
or nontreatment -emergent. A nontreatment -emergent AE is any  new sign or sym ptom , 
disease, or other untoward medical event that begins after written informed consent has been 
obtained but before the subject has received invest igational product. 
Elect ive treatment or surgery ,or preplanned treatment or surgery  (that was scheduled prior to 
the subject being enro lled into the study ) for a docum ented pre -existing condit ion that di d not 
worsen from baseline is not considered an AE (serious or nonserious). An untoward medical 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
65of 98 Template 16.2event occurring during the prescheduled elect ive procedure or routinely scheduled treatment 
shoul d be recorded as an AE or SAE.
5.2 Definition of Serious Adverse Events
An SAE is any  AE that:
•Results in death
•Is immediately life -threatening
•Requi res inpat ient hospi talizat ion or prolongat ion of exist ing hospi talizati on 
•Results in persistent or significant disabilit y/incapacit y 
•Is a congenital ano maly/birth defect in o ffspring of the subject
•Is an important medical event that may jeopardize the subject or may require medical 
intervent ion to prevent one of the outcomes li sted above
Medical or scient ific judgment should be exercised in deciding whether expedited reporting 
is appropriate in this situation. Examples o f medically important events are intensive 
treatm ent in an emergency  room  or at hom e for allergi c bronchospas m, blood dy scrasias, or 
convulsio ns that do not result in hospitalizat ions; or development of drug dependency  or drug 
abuse.
5.3 Definition of Adverse Events of Special Interest
An AESI is one of scientific and medical interest specific to understanding of the
investigat ional product and may  require cl ose m onitoring and collect ing addit ional 
inform ation by the invest igator. An AESI may be serious or nonserious. The rapid reporting 
of AESIs allows ongoing surveillance of these events in order to characterize and understand 
them in associ ation with the use of this invest igational product.
The fo llowing AESIs will be particularly  monitored in this study  (see the Safety Handling
Plan for instructi ons and timing on complet ing any additional informat ion required for 
specific t ypes o f events related to the categories noted below ):
•Thrombo tic and embo lic events 
•Hepati c funct ion abnormalit y(meet ing the definit ion of HL as described in 
Secti on5.6.2 ).
•Anaphylaxis and seri ous hypersensit ivity react ions
•Immu ne com plex disease 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
66of 98 Template 16.2•Infusio n-related reacti ons
•Serious and /oropportunistic infect ions (including but not limited to reactivat ion of latent 
viral infect ion [VZ/HSV/ , EBV/CMV] and TB )
5.4 Recording of Adverse Events
AEswill be recorded on the eCRF using a recognized medical term or diagnosis that 
accurately reflects the event. AEs will be assessed by  the investi gator f or severit y, 
relationship to the invest igational product, possible etiologies, and whether the event meets 
criteria of an SAE and therefore requires immediate notificat ion to the sponsor (see Section 
5.5). See Section 5.2for the definit ion of SAEs and Secti on 10.2 for guidelines for 
assessment of severit y and rel ationship. If an AE evo lves into a condit ion that m eets the 
regul atory  defini tion of  “seri ous,” i t will be reported on the SAE Report Form.
Infusio n of bio logical products is commo nly associated with infusio n-related reacti ons. 
Anaphylaxis and infusio n-related reacti ons have some co mmo n manifestations and may  be 
difficult to dist inguish fro m each other. Infusio n-related reactions are commo nly observed 
during or shortly after the first time exposure to therapeutic mAbs delivered through IV 
infusio n. These react ions are less co mmo n following subsequent exposures. Unlike 
infusio n-related reacti ons, anaphylaxis is a rare event, usually occurring after subsequent 
exposure to an ant igen, and it is most comm only accom panied by severe systemic skin and or 
mucosal react ions. The invest igator is advised to carefully examine symptoms of adverse 
reacti ons observed during or shortly  after exposure to MEDI4920, and consider the above 
ment ioned facts prior to making a final diagnosis. React ions occurring at the time of or 
shortly  after subsequent infusio ns of investigational product are to be judged by the 
investigator at his/her own discretion. For the investigator’s convenience and to facilitate 
consistenc y in judgments a copy  of the Nati onal Insti tute of  Allergy  and Infect ious Disease s 
(NIAID ) and Food Allergy andAnaphylaxis Network (FAAN) guidance for anaphylaxis 
diagnosis is provi ded in Section 10.3.
5.4.1 Time Period for Collection of Adverse Events
AEswill be co llected fro m time of signature of informed consent throughout the treatment 
period and including the fo llow-up peri od (Day 169) .
5.4.2 Follow -up of Unresolved Adve rse Events
Any AEs that are unresolved at the subject’s last visit in the study  are f ollowed up by  the 
investigator for as long as medically indicated, but without further recording in the eCRF. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
67of 98 Template 16.2MedImmune retains the right to request addit ional inform ationfor any  subject wi th ongoing 
AE(s)/SAE(s) at the end of the study , if judged necessary .
5.5 Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the 
investigat ional product, or to the study  procedure( s). All SAEs will be recorded in the eCRF.
If any SAE occurs during the course of the study , the invest igator or other site personnel will 
inform  the appropri ate sponsor representative(s) wit hin 1 day; ie, immediately but no later 
than 24 hours of when he or she beco mes aware of it.
The designated sponsor representative works with the invest igator to ensure that all the 
necessary  informat ion is provided to the sponsor patient safet y data entry  site wi thin 
1calendar day  of initial receipt for fatal and life -threatening events and within 5 calendar 
days of init ial receipt for all other SAEs.
For fatal  or life -threatening AEs where important or relevant informat ion is missing, active 
follow-up is undertaken immediately . Invest igators or other site personnel will inform 
sponsor representatives of any  follow-up inform ation on a previously reported SAE within 
1calendar day; ie, immediately  but no l ater than 24 hours of when he or she beco mes aware 
of it.
Once the invest igator or other site personnel indicates an AE is seri ous in the electroni c data 
capture (EDC) sy stem , an autom ated em ail alert is sent to inform the designated sponsor 
representative(s).
If the EDC system is not available, then the investigator or other study  site personnel  reports 
the SAE to the a ppropri ate sponsor representative by telephone. The sponsor representative 
will advise the investigator/study  site personnel how to proceed.
5.6 Other Events Requiring Immediate Reporting
5.6.1 Overdose
An overdose is defined as a subject receiving a dose of inv estigational product in excess of 
that specified in the Investigator’s Brochure, unless otherwise specified in this protocol.
•An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdos e eCRF module.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
68of 98 Template 16.2•An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose with a MedImmune invest igational product occurs during the course of the 
study , then the invest igator or other site personnel informs appro priate sponsor 
representatives immediately, or no later than 24 hours of when he or she beco mes aware of it.
The designated sponsor representative works with the invest igator to ensure that all relevant 
inform ation is provided to the sponsor’s patient safe ty data entry  site.
For overdoses associated with an SAE, the standard reporting timelines apply; see 
Secti on5.5. For other overdoses, reporting must occur within 30 days.
5.6.2 Hepatic Function Abnormality
Cases where a subject shows elevat ions in liver biochemistry  may require further evaluat ion 
and occurrences o f AST or ALT ≥ 3× ULN together with TBL ≥ 2× ULN m ay need to be 
reported as AESIs. R efer to Secti on 10.4 for further instruction on cases o f increases in liver 
biochemistry  and eval uation of  HL.
5.6.3 Pregnancy
All pregnancies and outcomes of pregnancy sh ould be reported to the sponsor.
5.6.3.1 Maternal Exposure
If a subject beco mes pregnant during the course of the stud y, the invest igational product 
shoul d be discont inued immediately .
Pregnancy itself is not regarded as an AE unless there is a suspicio n that the invest igational 
product under study  may have interfered with the effectiveness of a contraceptive 
medicat ion. Congenital abnormalit ies/birth defects and spontaneous miscarriages shoul d be 
reported and handled as SAEs. Elect ive abortions without complicat ions shoul d not be 
Shoul d the invest igator beco me aware of a pregnancy in the partner of a male study subject 
who has received invest igational product, then the investigator or o ther site personnel will 
inform  the appropri ate sponsor representatives within 1 day; ie, immediately but no later 
than 24 hours of when he or she beco mes aware of it.
The designated sponsor representative works with the invest igator to ensure that all rel evant 
inform ation is provided to the sponsor’s patient safety data entry site within 1 or 5 calendar 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
69of 98 Template 16.2days for SAEs (see Section 5.5) and wi thin 30 days for all oth er pregnancies. The same 
timelines apply  when the outcom e informati on is available.
The pregnancy reporting module in the eCRF is used to report the pregnancy  and the 
pregnancy outcome module is used to report the outcome of the pregnancy .
6STUDY AND DATA M ANAGEMENT
6.1 Training of Study Site Personnel
Before the first subject is entered into the study , a MedImmune representative will review 
and discuss the requirements of the Clinical Study  Protocol  and rel ated docum ents wi th the 
investigat ional staff and also train them in any study -specific procedures and system(s) 
utilized.
The principal i nvest igator will ensure that appropriate training relevant to the study is given 
to all of these staff, and that any  new informat ion relevant to the performance of this stud y is 
forwarded to the staff invo lved.
The p rincipal invest igator will maintain a record of all individuals invo lved in the study  
(medical, nursing ,and other staff).
6.2 Monitoring of the Study
During the study , a MedImmune representative will have regular con tacts wi th the study  site, 
including visits to:
•Provi de inform ation and support to the invest igator(s) .
•Confirm that facilit ies remain acceptable .
•Confirm that the invest igational team  is adhering to the protocol, that data are being 
accurately and timely recorded in the eCRFs, that bio logical  samples are handled in 
accordance with the Laboratory  Manual ,and that investigational product accountabilit y 
checks are being performed .
•Perform  source data verification (a comparison of the data in the eCRFs with th e 
subject’s medical records at the hospital or practice, and other records relevant to the 
study ) incl uding verificat ion of informed consent of part icipating subjects. This will 
requi re direct access to all original records for each subject (eg, clinic cha rts).
•Ensure withdrawal of informed consent to the use of the subject’s bio logical  samples is 
reported and bio logical  samples are i dentified and disposed of/destroyed accordingly, and 
the acti on is docum ented, and reported to the subject.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
70of 98 Template 16.2The MedImmune re presentative will be available between visit s if the invest igator(s) or other 
staff at the cent erneeds information and advice about the study conduct.
6.2.1 Source Data
Refer to the Clinical Study  Agreement for l ocati on of  source data.
6.2.2 Study Agreements
The prin cipal  invest igator at each cent ershould comply wit h all the terms, condit ions, and 
obligat ions of the Clinical Study  Agreement, or equivalent, for this study . Ifthere is any 
inconsistency between this Clinical Study  Protocol and the Clinical Study  Agreem ent, the 
terms of Clinical Study  Protocol  shall  prevail wi th respect to the conduct of the study  and the 
treatm ent of subjects and in all other respects, not relat ing to study conduct or treatment of 
subjects, the terms of the Clinical Study  Agreement shal l prevail.
Agreem ents between MedImmune and the principal i nvest igator must be in place before any 
study -related procedures can take place, or subjects are enrolled.
6.2.3 Archiving of Study Documents
The i nvest igator follows the principles outlined in the Clini cal Study  Agreement.
6.3 Study Timetable and End of Study
An individual subject will be considered to have completed the study if the subject was 
followed through thelast protocol -specified visit/assessment (including telephone contact ),
regardl ess of the number of doses of invest igational product that was received.
Subjects will be considered not to have co mpleted the study  if consent was withdrawn or the 
subject was lost to fo llow-up (see Secti on 4.1.5 andSecti on4.1.6 ).
The end o f the study  (“study  com pletion”) is defined as the date of the last protocol -specified 
visit/a ssessment (including telephone contact) for the last subject in the study . 
6.4 Data Management 
Data m anagement will be performed by the MedImmune Data Management staff according 
to the Data Management Plan .
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
71of 98 Template 16.2A Web Based Data Capture system will be used for da ta collect ion and query  handling. The 
investigator will ensure that data are recorded on the eCRFs as specified in the study  protocol  
and in accordance with the instructions provided.
The invest igator ensures the accuracy, completeness, and timeliness of t he data recorded and 
of the provisio n of answers to data queries according to the Clinical Study  Agreement. The 
investigator will sign the completed eCRFs. A copy  of the com pleted eCRFs will be archived 
at the study  site.
6.5 Medical Monitor Coverage
Each subj ect will be provided wit h contact information for the principal invest igator. In 
addition, each subject will receive a toll -free number intended to provide the subject’s 
physician access to a medical mo nitor 24 hours a day , 7 day s a week in the event of an
emergent si tuation where the subject’s healt h is deemed to be at risk. In this situation, when a 
subject presents to a medical facilit y where the treating physician or health care provider 
requi res access to a phy sician who has knowledge of the invest igational product and the 
Clinical Study Protocol ,and the principal invest igator is not available, the treating physician 
or health care provider can contact a medical mo nitor through this system, which is managed 
by a third-party  vendor.
7ETHICAL AND REGULATO RY REQUIREMENTS
7.1 Ethical Conduct of the Study
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/G CP, and applicable regulatory  
requi rements.
7.2 Subject Data Prote ction
The Informed Consent Form (ICF) will incorporate (or, in so me cases, be acco mpanied by a 
separate document incorporating) wording that complies wit h relevant data protection and 
privacy  legislat ion.
MedImmune will not provide individual genoty pe resu lts to subjects, any  insurance 
company, any emplo yer, thei r family members, general physician or any  other thi rd party , 
unless required to do so by  law.
Extra precautions are taken to preserve confident iality and prevent genetic data being linked 
to the i dentity of the subject. In except ional circumstances, however, certain individuals 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
72of 98 Template 16.2might see both the genet ic data and the personal ident ifiers of a subject. For example, in the 
case of a medical emergency, a MedImmune medical mo nitoror an invest igator mig ht know 
a subject’s ident ity and also have access to his or her genetic data. Also regulatory  authori ties 
may require access to the relevant files, though the subject’s medical information and the 
genet ic files would remain physically separate .
7.3 Ethics and Regulatory Review
An IRB/IEC shoul d approve the final study  protocol , including the final versio n of the ICF
and any  other wri tten inform ation and/or materials to be provided to the subjects. The 
investigator will ensure the distribut ion of these documents to the applicable IRB/IEC, and to 
the study  site staff.
The opinio n of the IRB/IEC should be given in writing. The investigator should submit the 
written approval  to MedImmune before enrol lment of any  subject into the study . 
The IRB/IEC should approve al l advertising used to recruit subjects for the study .
MedImmune should approve any modificat ions to the ICF that are needed to meet local 
requi rements.
If required by  local regulat ions, the protocol should be re -approved by the IRB/IEC annually.
Before enr ollment of any  subject into the study , the final study  protocol , including the final 
versio n of the ICF ,is approved by the nat ional regulatory  authori ty or a notification to the 
national regulatory  authori ty is done, according to local regulations.
MedImmune will handle the distribut ion of any  of these documents to the national regulatory  
authori ties.
MedImmune will provide regulatory  authori ties, the IRB/IEC ,andprincipal i nvest igators 
with safet y updates/reports according to local requirements, in cluding suspected unexpected 
serious adverse reactions ,where relevant.
Each principal invest igator is responsible for providing the IRB/IEC with reports of any 
serious and unexpected adverse drug reactions from any  other study  conducted wi th the 
investigat ional product. MedImmune will provide this informat ion to the principal 
investigator so that he/she can meet these reporting requirements.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
73of 98 Template 16.27.4 Informed Consent
The principal i nvest igator(s) at each cent erwill:
•Ensure each subject is given full and a dequate oral and written information about the 
nature, purpose, possible risk and benefit of the study .
•Ensure each subject is notified that he/she isfree to discont inue from the study  at any  
time.
•Ensure that each subject is given the opportunit y to ask questions and allowed time to 
consider the information is provi ded.
•Ensure each subject provides signed and dated info rmed consent before conducting any 
procedure specifically  for the study .
•Ensure the original, signed IC F(s) is/are stored in the invest igator’s study  file.
•Ensure a copy  of the signed ICF is given to the subject .
•Ensure that any  incentives for subjects who participate in the study  as well  as any  
provi sions for subjects harmed as a consequence of study  parti cipat ion are described in 
the ICF that is approved by an IRB/IEC .
7.5 Changes to the Protocol and Informed Consent Form
Study  procedures will not be changed wit hout the mutual agreement of the principal 
investi gator and MedImmune .
If there are any substant ial changes to the study  protocol , then these changes will be 
docum ented in a study  protocol  amendment and where required in a new versio n of the study  
protocol .
The am endment i s to be approved by  the relevant IRB/IEC and if applicable, also the 
national regulatory  authori ty, before implementa tion. Local  requi rements are to be followed 
for revised protocols.
MedImmune will distribute any  subsequent am endments and new versio ns of the protocol to 
each principal i nvest igator (s). For distribution to the IRB/IEC see Section 7.3.
If a protocol amendment requires a change to a site’s ICF, MedImmune and the site’s 
IRB/IEC are to approve the revised ICF before the revised form is used. 
If local regulat ions requi re, any  administrative change will be communicated to or approved 
by each IRB/IEC.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
74of 98 Template 16.27.6 Audits and Inspections
Authori zed representatives of MedImmune, a regulatory  authori ty, or an IRB/IEC may 
perform  audi ts or i nspect ions at the cent er, including source data verificat ion. The purpose of 
an audit or inspect ion is to sy stematically and independent ly examine all study -related 
activit ies and documents, to determine whether these activit ies were conducted , and data 
were recorded, analyz ed,and accurately reported according to the protocol, GCP, guidelines 
of the ICH, and any  applicable regulatory  requi rements. The invest igator will contact 
MedImmune immediately  if contacted by  a regul atory  agency  about an inspect ion at the site.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
75of 98 Template 16.28REFERENCES
Alaaeddine N, Hassan GS, Yacoub D, Mourad W. CD154: an immuno inflammatory 
mediator in systemic lupus ery thematosus and rheumatoid arthritis. Clin Dev Immunol. 
2012;2012:490148. doi: 10.1155/2012/490148. Epub 2011 Oct 24. 
Aletaha D, Neogi T, Silman AJ, Fun ovits J, Felson DT, Bingham CO 3rd, et al. 2010 
rheumatoi d arthri tis classificat ion criteria: and Ameri can Co llege of Rheumatology/European 
League Against Rheumat ism co llaborative init iative. Arthrit is Rheum. 2010;62(9):2569 -81.
Berner B, Wo lf G, Hummel KM , Muller GA, Reuss -Borst MA. Increased expressio n of 
CD40 ligand (CD154) on CD4+ T cells as a marker of disease activit y in rheumatoid 
arthri tis. Ann Rheum  Dis. 2000;59(3):190 -5. 
Boum pas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A; BG 9588 
Lupus Nephrit is Trial Group. A short course of BG9588 (anti -CD40 ligand ant ibody ) 
improves sero logic activit y and decreases hematuria in patients with proliferative lupus 
glomerulonephri tis. Arthri tis Rheum. 2003;48(3):719 -27.
Bretz F, Pinheiro JC, Br anson M. Combining mult iple co mpar isons and modeling techniques 
in dose -response studies. Bio metrics. 2005;61(3):738 -48.
Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthrit is: 
from pathogenic players to disease bio markers. Biom ed Res Int. 2014;2014:681678. doi: 
10.1155/2014/681678. Epub 2014 Apr 29. 
National Center for Immunizat ion and Respiratory Diseases. General reco mmendat ions on 
immunizat ion practices -recommendatio ns of the A dvisory  Commi ttee on Immunizat ion 
Practi ces (ACIP). MMWR Reco mm Rep. 2011 :60(2):1-64.
Chamberlain C, Urowitz M, Soranson J, Wat ling M, Colman P, Harari O, et al. Repeated 
administrati on of  dapirolizumab pegol (DZP) appears safe and well tolerated in patients with 
systemic lupus ery thematosus (SLE ) and is acco mpanied by an improvement in disease 
activit y: results fro m a phase 1 s tudy [abstract]. Arthrit is Rheumatol. 2015;67(suppl 10).
Croft M, Benedict CA, Ware C.F. Clinical targeting of the TNF and TNFR superfamilies. 
Nature Rev Drug Discov. 2013; 12(2):147 -68. doi : 10.1038/nrd3930. Epub 2013 Jan 21.
Ford ML, Adams AB, Pearson TC. Targeting co -stimulatory  pathways: transpl antati on and 
autoimmunit y. Nat Rev Nephro l. 2014;10(1):14 -24. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
76of 98 Template 16.2Galindo -Rodri guez G, Avina -Zubieta JA, Russell AS, Suarez -Almazor ME. Disappoint ing 
longterm result s with disease m odifying ant irheumati c drugs. A practice based study . J 
Rheumatol. 1999;26(11):2337 -43.
Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al., Elevated serum 
soluble CD40 ligand in cancer pat ients may play an immunosuppressive role, Blood. 
2012:120(15):3030 -38.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al; TEMPO 
(Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study  
investigators. Thera peuti c effect of the combinat ion of etanercept and methotrexate 
compared wi th each treatm ent al one in patients with rheumatoid arthrit is: double -blind 
rando mised controlled trial. Lancet. 2004;363(9410):675 -81.
Kuwana M, Nomura S, Fujimura K, Nagasawa T, M uto Y, Kurata Y, et al. Effect of a single 
inject ion of humanized anti -CD154 m onoclonal antibody  on the pl atelet -specific 
autoimmune response in pat ients with immune thrombocy topeni c purpura. Bl ood. 
2004;103(4):1229 -36. Epub 2003 Oct 9.
Langer F, Ingerso llSB, A. Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, et al. The role 
of CD40 in CD40L -and ant ibody -mediated platelet activat ion. Thromb Haem ost. 
2005;93(6):1137 -46.
Li G, Di ogo D, Wu D, Spoonamore J, Dancik V, Franke L, et al. Human genet ics in 
rheumato id arthrit is guides a high -throughput drug screen of the CD40 signaling pathway . 
PLoS Genet. 2013;9(5):e1003487. 
Listing J, Strangfeld A, Rau R, Kekow J, Gromnica -Ihle E, Kl opsch T, et al . Clinical and 
funct ional remissio n: even though bio logics are super ior to conventional DMARDs overall 
success rates remain low --resul ts from RABBIT, the German bio logics register. Arthrit is Res 
Ther. 2006;8(3):R66. Epub 2006 Apr 5.
Maetzel  A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US 
rheumatol ogists treat m oderate or aggressive rheumatoid arthritis: a survey. J Rheumatol. 
1998;25(12):2331 -8.
Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. 
Modified disease act ivity scores that include twenty -eight -joint coun ts: develop ment and 
validat ion in a prospective longitudinal study  of patients wi th rheumatoi d arthri tis. Arthri tis 
Rheum . 1995;38(1):44 -8.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
77of 98 Template 16.2Robl es-Carrillo L, Meyer T, Hatfield M, Desai H, Davila M, Langer F, et al Ant i-CD40L 
immune complexes potently  activate platel ets in vitro and cause thrombosis in FCGR2A 
transgenic mice. J Immuno l. 2010;185(3):1577 -83. doi: 10.4049/jimmuno l.0903888. Epub 
2010 Jun 28.
Scheinman R. NF -κB and Rheumatoi d Arthri tis: Will Understanding Genetic Risk Lead to a 
Therapeut ic Reward? For Imm unopathol  Dis Therap. 2013;4(2):93 -110.
Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, et al. CDP7657, an anti -
CD40L antibody  lacking an Fc dom ain, inhibit s CD40L -dependent immune responses 
without thromboti c com plicat ions: an in vivo study . Arthritis Res Ther. 2015; 17:234.
Singh JA, Christensen R, Wells GA, Suarez -Alma zor ME, Buchbinder R, Lopez -Olivo MA, 
et al. Biologics for rheumatoid arthrit is: an overview of Cochrane reviews. Cochrane 
Database Syst Rev. 2009;(4):CD007848. 
Symmo ns DP. Epidemi ology of rheumatoi d arthri tis: determinants of onset, persistence and 
outcom e. Best Pract Res Clin Rheumatol. 2002;16(5):707 -22.
Tarner IH, Neumann E, Gay  S, Fathm an CG, Muller -Ladner U. Developing the concept of 
adoptive cellular gene therapy  of rheumatoi d arthriti s. Autoimmun Rev. 2006;5(2):148 -52. 
Epub 2005 Oct 3.
Tocoi an A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley  R, et al . First-in-human 
trial of the safet y, pharmacokinet ics and immunogenicit y of a PEGylated anti -CD40L 
antibody  fragment (CDP7657) in healt hy individuals and patients with systemic lupus 
erythematosus. Lupus. 2015; 24(10):1045 -56. doi: 10.1177/0961203315574558. Epub 2015 
Mar 16.
van Baarsen LG, de Hair MJ, Ramwadhdoebe TH, Zijlstra IJ, Maas M, Gerlag DM, Tak PP. 
The cellula r com position of  lymph nodes in the earliest phase of inflammatory  arthri tis. Ann 
Rheum  Dis. 2013;72(8):1420 -4. doi :10.1136/annrheumdis -2012 -202990. Epub 2013 May  9.
Weinblatt ME, Key stone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. 
Adalimuma b, a fully human ant i-tumor necrosis factor alpha mo noclonal antibody , for the 
treatm ent of rheumatoid arthrit is in pat ients taking concomitant methotrexate: the ARMADA 
trial. Arthritis Rheum. 2003;48(1):35 -45.
Wells P and Anderson D. The diagnosis and tre atment of venous thromboembo lism. 
Hem atology Am Soc Hem atol Educ Program . 2013 ;2013 :457-63.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
78of 98 Template 16.2Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smo len J, et al . Validat ion of the 
28-joint Disease Act ivity Score (DAS28) and European League Against Rheumat ism 
response criteria based on C -reactive protein (CRP) against disease progression in pat ients 
with rheumatoi d arthri tis, and co mpar ison with the DAS28 based on ery throcyte 
sedimentation rate. Ann Rheum Dis. 2009;68(6):954 -60.
Wong JB, Ramey DR, Singh G. Long -term morbidi ty, mortali ty, and econo mics of 
rheumatoi d arthri tis. Arthri tis Rheum. 2001;44(12):2746 -9.
Zhang B, Wu T, Chen M, Zhou Y, Yi D, Guo R. The CD40/CD40L system: a new 
therapeuti c target for di sease. Immuno l Lett. 2013;153(1 -2):58 -61.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
79of 98 Template 16.29CHANGES TO THE PROTOCOL
All changes described below have been incorporated into the current version of the protocol.
Protocol Amendment 3, 29Sep 2017
In the original protocol  (dated 15Jan2016 ), 3 dose levels o f MEDI4920 (75 m g [Cohort 1], 
500mg [Cohort 2], or 1500 m g [Cohort 3]) or placebo were planned to be administered Q2W 
in combinat ion with MTX or another cDMARD for up to 12 weeks. An option to include a 
fourth dose cohort (dose not to exceed 1500 mg Q2W ) was also included in the original 
protocol ,if required, t o further characterize the dose -response relat ionship. 
After review of the primary  analysis data, whi ch incl uded cumulat ive safet y, PK, and 
biomarker data through Cohort 3,Day 85, the decision was made to explore afourth dose 
(Cohort 4, selected to be 1000mg Q2W) to better characterize the dose-response
relationship . The changes in this protocol amendment are a result of the addit ion of this 
fourth cohort and are outline dbelow:
1.Protocol  Synopsi s:Updated wording in the Study Design, T reatment Groups and 
Regimen, Statistical Analysis Methods sections of the synopsis to include the addit ion of 
Cohort 4
2.Secti on 1.6 (Potenti al Risks ); Secti on 3.1 .1 (Overview); Section 3.1.3 (Dose Escalat ion 
and Cohort Progression); Section 4.1.1 (Number of Subjects) :Modified the language to 
reflect the addit ion of fourth dose cohort (1000 mg Q2W). 
3.Figure 3.1.1 -1 (Study Flow Diagram): Modified the study  design diagram to include the 
fourth dose cohort (1000 mg Q2W).
4.Secti on 3.1.2 (Treatm ent Regimen): Added the treat ment regimen for Cohort 4 including 
the dose (1000 mg), and duration of the IV infusio n (90minutes on Days 1, 15, 29, 43, 
57, 71, and 85). 
5.Secti on 3.2.1 (Dose Rationale): Added addit ional language to explain that the rationale 
for the sel ection of the 10 00mg Q2W dose for Cohort 4 was based on PK -PD m odeling 
data from  Cohorts 1 to 3 as well as clinical judgement and that the dose is expected to 
resul t in a clinical response comparable to the highest dose in the study  (1500 m g Q2W) 
but with a larger safet ymargin. 
6.Secti on 4.5.1.5 (Preparati on of  Intravenous Dose); Section 4.5.1.6 (Intravenous 
Administrati on): Updated the IV dose preparation and administration language to include 
the 1000 mg dose and the appropriate vo lume and duration of the IV infusio nin
Cohort 4. 
7.Secti on 4.6.4 (Unblinding for Interim Analysis Purposes) ; Section 4.8.6 (Interim 
Analysis): Updated the language to reflect the addition of the fourth cohort.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
80of 98 Template 16.28.Secti on 4.8.2 (Sample Size and Power Calculat ions):Updated the language to reflect the 
addition of  the f ourth cohort and the resultant change in the power calculations fro m 80% 
to 92% . 
Protocol Amendment 2, 10 Aug2016
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 2. Main changes to the protocol are summarized below:
1.Protocol  Synopsi s; Section 3.1.1 (Overview): Updated wording to reflect the current 
number of countries planned for this study; revised wording to clarifythat while an 
overnight stay  prior to administration of invest igational product on Day  1is
recommended, it is not mandatory . This revisi on was m ade to allow sites the flexibilit y to 
perform  all pre -dose study  procedures on the same day  as the day  of invest igational 
product administration if abso lutely necessary .
2.Secti on 4.1 .2 (Inclusio n Cri teria): Modified Inclusion Criterion # 4to allow a co mbinat ion 
of cDMARDs if reco mmended by nat ional guidelines and/or standard medical pract ice
instead of just a single cDMARD as outlined in the original protocol ; modified Inclusi on 
Criterion #9 to rem ove the specific numerical thresho lds for the detection of RF -IgM and 
ACPA 2positivity that were included in the original protocol and instead include a 
generic statement about serum RF and ACPA positivit y to accomm odate the different 
ranges of detecti on that m ay be exhibi ted by the assays used by  the central  laboratory . 
3.Secti on 4.1.3 (Excl usion Criteria): Corrected a ty pographi cal error in Exclusi on 
Criterion#10 by changing “intermediate” to “indeterminate”. Because MEDI4920 is a 
CD40L anta gonist, Exclusio n Cri terion #17 was updated to specify that subjects who had 
undergone previous treatment with ant i-CD40/CD40L agents will also be excluded from 
participat ion in the study.
4.Table 4.2.1 -1(Schedule of Screening Procedures) , Table 4.2.2 -1(Schedule of Treatment 
Period Study  Procedures) , and Table 4.2.3 -1(Schedule of Follow -up Procedures) : Added 
a footnote to specify  that ESR will be analyzed at the local laboratories.
5.Table 4.2.2 -1: Added a note to specify that an overnight stay  prior to admi nistrati on of  
investigat ional product on Day  1 is recommended but not mandatory  whereas an 
overnight stay  post -investigational product administration on Day 1 is mandatory.
6.Secti on 4.3.2 (Clinical Laboratory Tests): Corrected a typographical error by chang ing 
the abbreviation for total bilirubin fro m “TLB” to “TBL”.
7.Secti on4.5.1.5 (Preparation of Intravenous Dose): Added sub -headings to clearly 
different iate between the MEDI4920 and placebo dose preparation steps; relocated the 
following sentence “A vial s hould be use donly one time to prepare a single dose” to the 
MEDI4920 sub -section for clarificat ion as no vials are used for the placebo treatment. 
Protocol Amendment 1, 05Apr 2016
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 1. Main changes to the protocol are summarized below.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
81of 98 Template 16.21.Protocol  Synopsi s, Secti on2.2.1 (Prim ary Endpoints) : Revised wording for AESIs to be 
consistent with the standard potenti al risks language used in other clinical programs in 
MedImmune/Astra Zeneca and in other MEDI4920 regulatory  documents ; added 
additional language for serious and /oropportuni stic infections to clarify that the 
evaluat ions are not limited to just VZ, HSV, EBV, EMV, and TB . These change swillnot 
affect the actual endpo ints that are planned to be evaluated in the study or the safet y 
monitoring of these events .
2.Secti on1.6 (Potenti al Risks): Revised wording pertaining to the potential risks asso ciated 
with MEDI4920 for consistency  with the aforem entioned changes in the AESI language; 
based on recommendat ions from the United States Food and Drug Administrati on(US 
FDA) , the l anguage pertaining to thromboembo lic events was modified by adding the 
phrase “or suspected” such that dose escalat ion will be suspended even in the case of a 
suspected thromboembo lic event , until addit ional data allow an informed diagnosis of the 
event to be m ade.
3.Secti on3.1.1 (Overview) ; Sect ion6.2 (Monitoring of the Study ): Changed the term 
“study  drug” to “invest igational product” for consistency wit h wording in the protocol. 
4.Secti on3.1.3 (Dose Escalat ion and Cohort Progression): Based on recommendations 
from the US FDA , the language in the first dose escalat ion criterionwas m odified such 
that dose escalation woul d be suspended even in the case of a suspected thromboembo lic 
event; addit ional language regarding the use of a diagnosis algorithm for determining a 
likely  thromboembolic event was added to the first criterion ;modified the second dose 
escalat ion criterion such that dose escalat ion would be suspended if 2 subjects (instead of 
3) dosed with MEDI4920 in a single cohort experiences either a Grade 3 or higher TEAE 
of the sam e type or any  SAE.
5.Secti on4.1.6 (Di scont inuation of Invest igational Product): Revised the language 
pertaining to anaphylaxis/serious hypersensit ivity reacti ons, seri ous/opportuni stic 
infect ions, and thromboembo lic event sfor consistency wit h the aforement ioned changes.
6.Secti on4.2.2 (Treatm ent Pe riod); Table 4.2.2 -1: Modified wording in the text and table 
note to clarify that all laboratory  sample collect ions and assessments on dosing day  
“must ”(instead of “should”) be perform ed at predose, unl ess specified otherwise.
7.Secti on5.3 (Definit ion of A dverse Events of Special Interest): Clarified statement 
regarding fo llow-up for AESIs: i ndicated that clinical monitoring of AESIs will be 
perform ed under theinstructi ons of the “Safet y Handling Pl an”, instead of “Medical  
Moni toring Pl an”andthat AESIs will notbe reported in detail inthe eCRF, as stated in 
the original protocol ;revised wording for AESIs to harmonize it with standard language 
used in other clinical programs in MedImmune/Astra Zeneca and for consistency wit h the 
changes mentioned above.
8.Secti on8 (References): Based on the changes in the amendment per recommendat ions 
from the US FDA , an addi tional reference was added to support the algorithm for 
diagnosing a DVT/PE event.
9.Appendix 4; Section 10.4.2.3: (Identification of Potential Hy’s Law Cases);
Secti on10.4.4 (Revi ew and Assessment of Potential Hy’s Law Cases ): Rem oved the 
laboratory  eCRF as one of the ty pes of docum ents in which laboratory  data are entered as 
it was incl uded in error , and replaced it with the correct document, “Medical Moni toring 
Plan”.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
82of 98 Template 16.210.Appendix 5 ; Section 10.5 (Di agnosis of a Potential Thromboembolic Event) : Based on 
the changes in the amendment per recommendat ions from the US FDA , an addi tional 
Appendix was added to describe in detail the algorit hm that will be used to determine the 
likelihood of a DVT/PE event.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
83of 98 Template 16.210APPENDICES
10.1 Appendix 1 -Signatures
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
84of 98 Template 16.2Sponsor Signature(s)
A Phase 1b Rando mized, Double -blind, Placebo -controlled Mult iple-ascending Dose Study  
to Eval uate the Safet y, Tolerabilit y, Pharmacokinetics, Immunogenic ity, Pharmacodynamics ,
and Clinical Response of MEDI4920 in Subjects wit h Adult -onset Rheumatoid Arthrit is
I agree to the terms of this protocol.
Signature and date: electroni c signature appended
Jorn Drappa, MD, Ph.D., , Clinical Development
One MedImmune Way, Gait hersb urg, MD, 20878, USA
Telephone number: 
PPD
PPD
PPD
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
85of 98 Template 16.2Signature of Principal Investigator
A Phase 1b Rando mized, Double -blind, Placebo -controlled Mult iple-ascending D ose Study  
to Eval uate the Safet y, Tolerabilit y, Pharmacokinetics, Immunogenicit y, Pharmacodynamics ,
and Clinical Response of MEDI4920 in Subjects wit h Adult -onset Rheumatoid Arthrit is
I, the undersign ed, have reviewed this protocol and I agree to conduct this protocol in 
accordance with ethical principles that have their origin in the Declarat ion of Helsinki and 
are consistent with the International Conference on Harmonisat ion gui delines on Good 
Clinical Practice, any applicable law s and requi rements, and any condit ions required by a 
regul atory  authori ty and/or Insti tutional Review Board/Independent Ethics Committee 
(IRB/IEC ). 
I understand that the protocol may not be modified without written approval of the sponsor. 
All changes to the protocol  must be submitted to the applicable regulatory  authori ty and 
IRB/IEC, and must be approved by  the IRB/IEC prior to implementation except when 
necessary  to eliminate immediate hazards to the subjects or when the change(s), as deemed 
by the spon sor, i nvolves only logist ical or administrative changes. Documentation of 
IRB/IEC approval must be sent to the sponsor immediately upon receipt.
Signature and date: 
Nam e and ti tle: 
Address including postal code: 
  
Telephone number: 
Site/Center Number (if available)
This document contains confidential information, which should not be copied, referred to, released, or published 
without written approval from MedImmune or AstraZeneca. Investigators are cautioned that the information in 
this protocol may be subject to change and revision.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
86of 98 Template 16.210.2 Appendix 2 -Additional Safety Guidance
Further Guidance on the Definition of a Serious Adverse Event
Life-threatening
‘Life -threatening’ means that the subject was at immediate risk of death from an AE as it 
occurred or it is suspected that use or continued use of the invest igational product would 
resul t in the subject’s death. ‘Life -threatening’ does not mean that had an AE occurred in a 
more severe form  it might have caused death (eg, hepat itis that resolved without hepat ic 
failure).
Hospitalization
Outpati ent treatm ent in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal edema). Hospital admissio ns and/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriora te in an 
unexpected way  during the study .
Important Medical Event or Medical Intervention
Medical and scientific judgment should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life thr eatening or result 
in death, hospitalizat ion, disabili ty or incapacit y but m ay jeopardi ze the subject or may  
requi re medical intervention to prevent one or more outcomes listed in the definit ion of 
serious. These shoul d usually  be consi dered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; 
medical judgment must be used.
Examples of such events are:
•Angioedema not severe enough to require intubation but requiring IV hydrocortisone 
treatm ent
•Hepatotoxicit y caus ed by paracetamo l (acetaminophen) overdose requiring treatment 
with N-acetylcysteine
•Intensive treatment in an emergency room or at home for allergic bronchospasm
•Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n) or convulsio ns 
that do not result in hospitalizat ion
•Development of drug dependency or drug abuse
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
87of 98 Template 16.2Assessment of Severity
Assessment of severit y is one of the responsibilit ies of the invest igator in the evaluation o f 
AEs and SAEs. The determinat ion of severit y should be m ade b y the invest igator based upon 
medical judgment and the severit y categori es of  Grades 1 to 5 as defined below.
Grade 1 An event of mild intensit y that is usually transient and may  
requi re only  minimal treatm ent or therapeuti c intervent ion. The 
event does no t generally interfere with usual act ivities o f daily 
living.
Grade 2 An event of moderate intensit y that is usually alleviated with 
additional specific therapeuti c interventi on. The event 
interferes wi th usual act ivities of daily living, causing 
discomfort but poses no significant or permanent risk of harm 
to the subject.
Grade 3 A severe event that requi res intensive therapeutic intervent ion. 
The event interrupts usual activit ies of daily living, or 
significant ly affects the clinical status of the subject.
Grade 4 An event, and/or its immediate sequelae, that is associated with 
an imminent risk of death or with physical or mental 
disabili ties that affect or limit the abilit y of the subject to 
perform  activities of daily living (eating, ambulat ion, toilet ing, 
etc).
Grade 5 Death (loss of life) as a result of an event.
It is important to dist inguish between serious criteria and severit y of an AE. Severit y is a 
measure of intensit y whereas seri ousness is defined by  the cri teria in Sect ion5.2. A Grade 3 
AE need not necessarily be considered an SAE. For example, a Grade 3 headache that 
persists for several hours may not meet the regulatory  defini tion of an SAE and would be 
considered a nonserious event, whereas a Grade 2 seizure result ing in a hospital admissio n 
woul d be considered an SAE.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
88of 98 Template 16.2Assessment of Relationship
Relationship to Investigational Product
The invest igator is required to provide an assessment of relat ionship of AEs and SAEs to the 
investigat ional product . The fo llowing factors shoul d be considered when deciding if there is 
a “reasonable possibilit y” that an AE may have been caused by the invest igational product.
•Did the subject actu ally receive the suspect invest igational product? Did the AE occur in 
a reasonable temporal relat ionship to the administration of the suspect invest igational 
product?
•Consistency wit h known invest igational product profile. Was the AE consistent with the 
previous knowledge of the suspect invest igational product (pharmaco logy and 
toxicology) or products of the same pharmacological class , OR coul d the AE be 
anticipated fro m its pharmaco logical properti es? Is this event frequently observed in the 
study  popul ation regardl ess of treatm ent?
•De-challenge experience. Did the AE resolve or improve on stopping or reducing the 
dose of the suspect invest igational product?
•No al ternative cause. The AE cannot be reasonably explained by another etio logy such as 
the underlyi ng disease, other drugs, or other host or environmental factors.
•Re-challenge experience. Did the AE reoccur if the suspected invest igational product was 
reintroduced after having been stopped? MedImmune would not normally recommend or 
support a re -challen ge.
•Laboratory  tests. Did a specific laboratory invest igation (if perform ed) confirm  the 
relationship?
A “reasonable possibilit y” coul d be considered to exist for an AE where one or more of these 
factors exi st.
If available informat ion describing the event and the circumstances is insufficient to make a 
definit ive assessment of causal association the nature of AE, and likelihood of this event 
occurring in the study  popul ation should be taken in toaccount ( eg,events not ty pically  seen 
in the study  popul ation are m ore likely  to lack an alternat ive explanation).
In contrast, there would not be a “reasonable possibilit y” of causalit y if none of the above 
criteria apply or where there is evidence ofexposure and a rea sonable t ime course but any 
de-challenge (if performed) is negat ive or ambiguous or there is another more likely cause of 
the AE.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
89of 98 Template 16.2In difficult cases, other factors could be considered such as:
•Is this a recognized feature of overdose of the investigat ionalproduct?
•Is there a known mechanism? Ambiguous cases should be considered as being a 
“reasonable possibilit y” of a causal relationship unless further evidence becomes 
available to refute this. Causal relat ionship in cases where the disease under study  has
deteri orated due to lack of effect should be classified as “no reasonable possibilit y”.
Relationship to Protocol Procedures
The invest igator is also required to provide an assessment of relat ionship of SAEs to protocol 
procedures on the SAE Report Form. This includes non -TESAEs (ie, SAEs that occur prior 
to the administration of invest igational product) as well as TESAEs . A protocol -related SAE 
may occur as a result of a procedure or intervention required during the study (eg, blood 
collect ion, washout of an exist ing medicat ion). The fo llowing gui delines shoul d be used by 
investigators to assess the relationship of SAEs to the protocol:
Protocol  related: The event occurred due to a procedure/intervention that was described 
in the protocol for which there i s no al ternat ive et iology  present in the 
subject’s medical record.
Not protocol related: The event is related to an etio logy other than the procedure/ 
intervent ion that was described in the protocol (the alternative et iology 
must be documented in the study subject’s medical record).
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
90of 98 Template 16.210.3 Appendix 3 -National Institute of Allergy and Infecti ous Diseases 
and Food Allergy and Anaphylaxis Network Guidance for 
Anaphylaxis Diagnosis
Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et al.
Second symposium on the definit ion and m anagement of anaphylaxis: Summary report --
Second National Inst itute of Allergy  and Infect ious Di sease/Food Allergy  and Anaphylaxis 
Network symposium. J Allergy  Clin Immunol . 2006;117:391 -7.
NIAIDs and FAAN define anaphylaxis as a serious allergic reaction that is rapid in onset and 
may cause death. They  recognize 3 categori es of anaphylaxis, with criteria designated to 
capture from 80% of cases (category  1) to > 95% of all cases of anaphylaxis (for all 3 
categori es). 
1.Acute onset of an illness (minutes to several hours) with invo lvement of the skin, 
mucosal t issue, or both (eg, generalized hives, pruritus or flushing, swollen lips -tongue-
uvula)
AND AT LEAST ONE OF THE FOLLOWING
a.Respiratory  com promise (eg, dyspnea, w heeze -bronchospasm, stridor, reduced peak 
expiratory  flow [PEF], hypoxemia)
b.Reduced BP or associated symptoms of end -organ dy sfunct ion (eg, hy potoni a 
[collapse], syncope, incont inence)
2.Two or more of the fo llowing that occur rapidly  after exposure to a lik ely allergen for 
that pati ent (minutes to several hours):
a.Involvement of the skin -mucosal t issue (eg, generalized hives, itch -flush, swollen 
lips-tongue-uvula)
a.Respiratory  com promise (eg, dyspnea, wheeze -bronchospasm, stridor, reduced PEF, 
hypoxemia)
b.Reduc ed BP or associated symptoms (eg, hy potonia [coll apse], syncope, 
incont inence)
c.Persi stent gastrointestinal symptoms (eg, crampy  abdominal  pain, vomi ting)
3.Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a.Infants and c hildren: low systolic BP (age specific) or greater than 30% decrease in 
systolic BP
b.Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease fro m that 
person’s baseline
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
91of 98 Template 16.210.4 Appendix 4 -Actions Required in Cases of Increases in Liver 
Biochemis try and Evaluation of Hy’s Law
10.4.1 Introduction
This appendix describes the process to be fo llowed in order to ident ify and appropriately 
report cases of HL. It is not intended to be a comprehensive guide to the management of 
elevated liver biochemistries. 
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The invest igator is responsible for determining whether a subject meets 
potenti al HL (PHL) cri teria at any  point during the study .
The invest igator pa rticipates, together with MedImmune clinical project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met. 
HL cri teria are m et if there is no alternat ive explanation for the elevat ions in liver 
bioche mistry  other than drug -induced liver injury (DILI) caused by the invest igational 
product. 
The invest igator is responsible for recording data pertaining to PHL/HL cases and for 
reporting AEs and SAEs according to the outcome of the review and assessment in line wit h 
standard safet y reporting processes.
10.4.2 Definitions
10.4.2.1 Potential Hy’s Law 
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN at any  point during the study  
following the start of investigational product irrespective of an increase in ALP.
10.4.2.2 Hy’s Law 
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other reason, other than 
the invest igational product, can be found to explain the combinat ion of increases; eg, 
elevated ALP indicat ing cholestasis, viral hepat itis, another drug. 
For PHL and HL the e levat ion in transaminases must precede or be coincident with (ie, on 
the sam e day) the el evation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
92of 98 Template 16.210.4.2.3 Identification of Potential Hy’s Law Cases
In orde r to identify cases of PHL, it is important to perform a comprehensive review of 
laboratory  data for any  subject who m eets any of the fo llowing i dentificat ion criteria in 
isolation or in combinat ion:
•ALT ≥ 3 × ULN
•AST ≥ 3 × ULN
•TBL ≥ 2 × ULN
When a subject meets any o f the identificat ion criteria, in isol ation or in combination, the 
central  laboratory  will immediately  send an alert to the investigator (also sent to sponsor 
study  representative). 
The invest igator will also remain vigilant for any local  laboratory  reports where the 
ident ificat ion criteria are met, where this is the case the invest igator will:
•Notify  the sponsor study  representative
•Request a repeat of the test (new blood draw) by  the central  laboratory
•Com plete the appropri ate u nscheduled laboratory  eCRF m odule(s) wi th the original  local 
laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the 
investigator will wit hout delay:
•Determine whether the subject meets PHL criteria by reviewing laboratory  reports from  
all previous visit s (including both central and local laboratory  resul ts)
The invest igator will, without delay, review each new laboratory report and if the 
ident ificat ion criteria are met will:
•Notify  the sponsor study  representative
•Determine whether the subject meets PHL criteria by reviewing laboratory  reports from  
all previous visit s
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
93of 98 Template 16.210.4.3 Follow -up
10.4.3.1 Potential Hy’s Law Criteria Not Met
If the subject does not meet PHL criteria the investigator will:
•Inform  the study  representative that the subject has not met PHL criteria
•Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided 
in the study  protocol .
10.4.3.2 Potential Hy’s Law Criteria Met
If the subject does meet PHL criteria the invest igator will :
•Determine whether PHL criteria were met at any  study  visit prior to starting study  
treatm ent 
•Notify  the sponsor study  representative who will then inform the study  team
The m edical  monitor contacts the invest igator, to provide guidance, discuss and agr ee an 
approach for the study  subjects’ foll ow-up and the continuous review of data. Subsequent to 
this contact the investigator will:
•Moni tor the subject until liver biochemistry  parameters and appropriate clinical 
symptoms and signs return to normal or ba seline levels, or as long as medically indicated 
•Invest igate the etio logy of the event and perform diagnostic investigat ions as discussed 
with the m edical m onitor. This includes deciding which tests available in the HL 
laboratory kit shoul d be used.
•If at any t ime (in consultat ion with the m edical  monitor) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures
10.4.4 Review and Assessment of Potential Hy’s Law Cases
The instructions in this sect ion shoul d be fo llowed for all cases where PHL cri teria are m et.
No later than 3 weeks after the biochemistry  abnormalit y was ini tially detected, the medical 
monitor will  contact the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ionfor meeting PHL criteria other than DILI caused by the 
investigat ional product. The medical mo nitor and Gl obal Safet y Physician will also be 
involved in this review together with other subject matter experts as appropriate. 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
94of 98 Template 16.2According to the outcome of th e review and assessment, the invest igator will fo llow the 
instructi ons bel ow.
If there is an agreed alternat ive explanat ion for the ALT or AST and TBL elevat ions, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly
whether the AE meets the criteria for an SAE:
•If the alternat ive explanat ion is not an AE, record the alternative explanation according to 
theMedical Monitoring Pl an
•If the alternat ive explanat ion is an AE/SAE, record the AE /SAE in the CRF accordingly 
and fo llow the sponsor’s standard processes
If it is agreed that there is noexplanat ion that would explain the ALT or AST and TBL 
elevations other than the invest igational product:
•Report an SAE (report term ‘Hy’s Law’) according to sponsor’s standard pr ocesses. 
◦The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious criteria 
apply
◦As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay, of o ver 3 weeks, in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternat ive explanat ion unt il such time as an informed decisio n can be made:
•Report an SAE (report term ‘Po tential Hy’s Law’) applying serious criteria and causalit y 
assessment as per above
•Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL c riteria are m et. Update the SAE report according to the outcome of the 
review .
10.4.5 Actions Required When Potential Hy’s Law Criteria Are Met Before 
and After Starting Study Treatment 
This sect ion is applicable to subjects with liver metastases who meet PHL c riteria on study  
treatm ent having previously  met PHL cri teria at a study  visit prior to starti ng study  treatm ent.
At the first on -study  treatm ent occurrence of PHL criteria being met the invest igator will:
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
95of 98 Template 16.2•Determine if there has been a significant change i n the subjects’ condit ion compared with 
the last visit where PHL criteria were met 
◦If there is no significant change no action is required
◦If there is a significant change , notify the study  representative, who will inform the 
central  study  team , then foll ow the subsequent process described in Sect ion10.4.3.2
A ‘significant’ change in the subject’s condit ion refers to a clinically  relevant change i n any 
of the individual liver biochemistry  parameters (ALT, AST, or TBL) in isolat ion or in 
combinat ion, or a clinically  relevant change in associated symptoms. The determinat ion of 
whether there has been a significant change will be at the discret ion of t he investigator ;this 
may be in consultat ion with the medical  monitor if there i s any  uncertaint y.
10.4.6 Actions Required for Repeat Episodes of Potential Hy’s Law
This sect ion is applicable when a subject meets PHL criteria on study  treatm ent and has 
already me t PHL cri teria at a previous on -study  treatm ent visi t.
The requi rement to conduct fo llow-up, revi ew, and assessment of a repeat occurrence(s) of 
PHL i s based on the nature of the alternat ive cause identified for the previous occurrence . 
The invest igator should determine the cause for the previous occurrence of PHL criteria 
being met and answer the fo llowing quest ion:
•Was the alternat ive cause for the previous occurrence o f PHL cri teria being met found to 
be the disease under study , eg, chronic or progress ing malignant disease, severe infect ion, 
or liver disease, or did the subject m eet PHL cri teria pri or to starting study  treatm ent and 
at thei r first on study  treatm ent visi t as described in Section 10.4.5 ?
If No: Follow the process described in 10.4. 3.1
If Yes: Determine if there has been a significant change in the subject’s condit ion compared 
with when PHL cri teria were previously  met:
•If there is no significant change no action is requir ed
•If there is a significant change fo llow the process described in Section 10.4.3.2
A ‘significant’ change in the subject’s condit ion refers to a clinically  relev ant change in any 
of the individual liver biochemistry  parameters (ALT, AST, or TBL) in isolat ion or in 
combinat ion, or a clinically  relevant change in associated symptoms. The determinat ion of 
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
96of 98 Template 16.2whether there has been a significant change will be at the dis cretion of the investigator; this 
may be in consultat ion with the medical  monitor if there i s any  uncertaint y.
10.4.7 References
The United States Food and Drug Administration Guidance for Industry  (issued July 2009) 
‘Drug -induced liver injury: Premarket ing c linical evaluat ion’:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidance
s/UCM174090.pdf
MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
97of 98 Template 16.210.5 Appendix 5 –Diagno sis of a Potential Thromboembolic Event
10.5.1 Clinical Probability Score of D eep Vein Thrombo sis-Wells Criteria
d = days; DVT = deep vein t hrombosis ; mo = mo nths; wk = weeks
Score ≤ 1 = DVT is clinically unlikely ; Score ≥ 2 = DVT is clinically likely
Algorithm for Suspected Deep Vein Thrombosis
In every  case of a clinically suspected deep vein thrombosis ( DVT ), the clinical probabilit y 
score must be calculated using by the aforem entioned Wells criteria and a D-dimer test m ust 
be performed . 
•If clinical probabili ty shows “DVT unlikely” (ie, score ≤1), and D -dimer value is ≤ULN, 
DVT isexcluded. 
•If clinical probabilit y shows “DVT unlikely” (ie, score ≤1), and D -dimer value is > ULN, 
compressi on ultrasound willbeperformed. 
◦If ultrasound shows no abnormal changes, DVT isexcluded. 
◦If ultrasound shows abnormal changes, compatible with thrombosis, DVT is
confirmed. 
◦If ultrasound is unavailable /equivocal and D -dimer is only increased at the ti me of 
event, DVT is considered “ likely ”. 
•If clinical  probabili ty shows “ DVT likely” (ie, score ≥2), com pressio n ultrasound will be 
performed irrespect ive the D -dimer value. 
◦If ultrasound shows no abnormal changes, ultrasound should be repeated within 
7days; if ul trasound again shows no abnorm al changes, DVT i s excluded. 

MedImmune Protocol D5100C00002 Amendment 3
MEDI4920 29Sep2017; Final
98of 98 Template 16.2◦If ultrasound shows abnormal changes co mpat ible with thrombosis, DVT is 
confirmed. 
◦If ultrasound is unavailable or equivocal ,DVT is consi dered “likely” . 
•Each situation that cannot be adjudi cated using the al gorithmabove will be considered as 
“DVT likely” and dose escalat ion will be suspended.
10.5.2 Clinical Probabili ty Score of Pulmonary Embolism -Wells Criteria
bpm = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism ; wk = week
Score ≤ 4 = PE is clinically unlikely; Score ≥4 = PE is clinically likely
Algorithm for Suspected Pulmonary Embolism :
In every  case of suspected pulmo nary embo lism ( PE), clinical probabilit y score must be 
calculated using by  the aforement ioned Wells criteria and a D-dimertestmust be performed .
•If clinical probabilit y shows “ PEunlikely ”(ie, score ≤4), and D-Dimer value is ≤ULN ,
PEis excluded.
•If clinical  probabili tyshows “PE likely” (ie, score ≥4)or D-dimer value is > ULN, chest 
X-Ray will be perform ed. 
◦If chest X -ray is normal , a vent ilation-perfusion (V/Q)scan will be performed.  
◦If chest X -Ray is abnormal, computeri zed tom ographic pulmo nary angi ography  
(CTPA) will be considered. 
◦If V/Q scan or CTPA are not available or equivocal , PE isconsidered “l ikely” unless 
clinical probabilit y shows “PE unlikely” and D -dimer is > ULN at previous time 
points during the study , including at baseline. 
•Each situation that cannot be adjudi cated using the al gorithm abovewill be considered as 
“PE likely” and dose esc alation will  be suspended . 
Adapted from Wells P and Anderson D. The diagnosis and treatment of venous 
thromboembo lism. Hematol ogy Am Soc Hematol Educ Program. 2013 ;2013 :457-63.
